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MATRICELLULARPROTEINSREGULATECELLFUNCTION:
STUDIES OF THROMBOSPONDINS 1 AND 2
Paul Bornstein
Professor Emeritus of Biochemistry and Medicine, University of
Washington
Matricellular proteins are present in the extracellular space, but do
not perform structural functions. Rather, they modulate cell-matrix
interactions and cell function by interacting with a wide variety of
cell-surface receptors, cytokines and growth factors. The term
‘dynamic reciprocity’ has been applied to this process. Thrombo-
spondins (TSPs) 1 and 2 resemble each other structurally and
have similar properties when used as purified proteins in assays in
vitro. However, physiologically they perform different functions,
as judged by the phenotypes of TSP1 and 2-null mice, and by the
fact that they do not compensate for each other in vivo. The latter
finding can be explained by the very different promoter sequences
in the thbs1 and thbs2 genes, which dictate different temporal and
spatial expression of the two proteins in animals.
This presentation will focus on the phenotype of the TSP2-null
mouse, as elucidated by studies conducted in my laboratory
during the past 10 years. In particular, I will emphasize the
importance of a homeostatic function for both TSP1 and TSP2 in
the inhibition of angiogenesis. This function, in contrast to the
ligation of the CD36 receptor, which reduces vascularity by
causing apoptosis of endothelial cells (EC), inhibits EC prolifer-
ation by a pathway that is initiated by interaction of TSPs with
the very low density lipoprotein (VLDL) receptor. In effect, one
can thus ‘slow a car down by braking rather than by driving it
over a cliff’
THE CCN FAMILY OF PROTEINS: STRUCTURE-FUNCTION
RELATIONSHIPS
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The CCN proteins are key signalling and regulatory molecules involved
in many vital biological functions including cell proliferation, angiogen-
esis, tumourigenesis and wound healing. How these proteins influence
such a range of functions remains incompletely understood, but is likely
related to their discrete modular nature and a complex array of intra–and
inter-molecular interactions with a variety of regulatory proteins and
ligands. Although certain aspects of their biology can be attributed to the
four individual modules that constitute the CCN proteins, recent results
suggest that some of their biological functions require co-operation
between modules. Indeed, the modular structure of CCN proteins
provides important insight into their structure-function relationships.
NUCLEOPHOSMIN/B23: A MULTIFUNCTIONAL REGULATOR
THAT DETERMINES THE FATE OF CCN2 mRNA
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CCN2/CTGFisamultifunctionalmoleculethathasbeenknown toplaya
central role in chondrocyte differentiation. During this process, the
expression of ccn2 is tightly regulated to confer a maximal level at
prehypertrophic—hypertrophic stages, in which the 3'-untranslated
region (UTR) of the mRNA is critically involved in mediating its
post-transcriptional regulation. In our previous studies, we found that a
40 kDa protein binding specifically to an RNA cis-element, 3'-100/50,
in the 3'-UTR of the chicken ccn2 mRNA regulated its intracellular
stability. Interaction of the 40 kDa protein and 3'-100/50 is enhanced in
proliferating chondrocytes, in which ccn2 mRNA is rapidly degraded;
whereas prolonged half life of ccn2 mRNA is observed in hypertrophic
chondrocytes, where the interaction of the 40 kDa-protein and 3'-100/50
is diminished. Collectively, the 40 kDa protein has been thought to be a
ccn2-specific mRNA destabilizer during chondrocyte differentiation.
Here, we finally identified this 40 kDa protein as nucleophosmin
(NPM)/B23. NPM is a nuclear-cytoplasmic shuttling protein that is
characterized by its multiple functionality. This protein has been known
asa histone chaperone, regulatorofribosomalRNA transcription, as well
as an RNA binding post-transcriptional regulator of gene expression. In
our hands, direct binding to NPM to 3'-100/50 was confirmed not only
by RNA EMSA and UV crosslinking assay, but also by RNA
immunoprecipitation analysis. By using recombinant chicken NPM,
we could successfully reconstitute the post-transcriptional regulation of
ccn2 by NPM in vitro and found that this regulation was more robust in
chondrocytes than fibroblasts. Furthermore, siRNA-mediated gene
silencing of NPM in vivo clearly showed enhanced ccn2 gene
expression and prolonged half life of the ccn2 mRNA, confirming the
functional property of NPM as a specific destabilizer of the ccn2 mRNA
in living cells.
The 5'-100/50 element, a target of NPM, is evolutionally conserved
among vertebrate species. Therefore, it is anticipated that NPM is a
critical regulator of CCN2 during endochondral ossification and
possibly, in other physiological and pathological states as well in
J. Cell Commun. Signal. (2008) 2:101–125
DOI 10.1007/s12079-008-0035-1mammals. To confirm/uncover these aspects, further investigation with
mammalian species is currently in progress.
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Micro RNA (miRNA) is a major class of non-coding RNAs that are
involved in a variety of biological events including development of a
number of tissues and organs in higher eukaryotes. In order to identify
miRNAs that regulate endochondral ossification, we searched for
miRNA candidates that were down-regulated in chondrocytic cells and
were predicted to target CCN2 family protein 2/connective tissue
growth factor (CCN2/CTGF), which has been known to promote
endochondral ossification and cartilage regeneration, by a combination
of microarray and in silico analyses. Five miRNAs were predicted to
target the Ccn2 3'-UTR. Among those candidates, expression of miR-
18a was found to be the most strongly repressed in chondrocytic cells.
Utilizing reporter gene constructs and a synthetic mature miR-18a
duplex, we experimentally confirmed an miR-18a target in the same
region in the 3’-untranslated region (UTR) of human Ccn2 as predicted
in silico. Also, the introduction of the miR-18a duplex efficiently
repressed the production of CCN2 in those cells. Interestingly, this Ccn2
silencing was conferred entirely at a translation stage without affecting
the steady-state mRNA level in chondrocytic HCS-2/8 cells; whereas
accelerated degradation of Ccn2 mRNA has been observed in human
breast cancer MDA-231 cells. Finally, transfected miR-18a duplex
significantly caused the repression of the mature chondrocytic pheno-
type. Our present study revealed a regulatory role for miR-18a in
chondrocytic differentiation through CCN2 and a variable mode of post-
transcriptional regulation of the same miRNA, which was dependent on
the cellular background.
CTGF/CCN-2 EXPRESSION INDUCED BY TGF-b
IS MODULATED THROUGH A MECHANISM DEPENDENT
OF DECORIN AND LRP-1
Claudio Cabello-Verrugio
1 and Enrique Brandan
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Duchenne Muscular dystrophy (DMD) is the most severe myopathy
characterized by degeneration of skeletal muscle fibers and its replacement
by connective tissue producing fibrosis. Connective tissue growth factor
(CTGF/CCN-2), one of the main inducers offibrosis is increased in skeletal
muscle of patients with DMD. Diverse extracellular growth factors have
been proposed to modulate the levels of CTGF, regulating the beginning
and progression of fibrosis. Among them we can find transforming growth
factor beta (TGF-b) which is augmented in skeletal muscle of DMD. In
skeletal muscle cells, we have demonstrated that CTGF expression is
increased by TGF-b. A regulator of TGF-b activity is decorin, a soluble
proteoglycan present is skeletal muscle which is endocytosed through its
receptor LDL-related prtein-1 (LRP-1). We have previously demonstrated
that decorin modulates the response of myoblasts to TGF-b.
In this study, we evaluated the participation of decorin and its receptor
LRP-1 in the regulation of CTGF expression induced by TGF-b in skeletal
muscle cells. TGF-b increased CTGF expression in a concentration
dependent fashion. Transfection experiments using a plasmid reporter for
CTGF transcriptional activity (pCTGF-luc) showed that myoblasts that
not express decorin (Dcn null) have 50% less response to TGF-b
compared to wild type myoblasts. This effect was rescued to the wild
type levels when Dcn null cells re-express decorin. Toevaluate if theeffect
of decorin in CTGF expression induced by TGF-b was mediated by LRP-
1, myoblasts wild type and Dcn null were co-transfected with a specific
siRNA for LRP-1 and the plasmid reporter pCTGF-luc. Under these
conditions, pCTGF-luc activity induced by TGF-b decreased only in cells
expressing decorin, but it was unchanged in Dcn null cells. The same
results were obtained when mRNA levels of CTGF induced by TGF-b
wereevaluated.TheseresultssuggestthatdecorinandLRP-1modulatethe
TGF-b-dependent expression of CTGF. Interestingly, wild type and Dcn
null cells incubated with a specific inhibitor of TGF-b receptor I kinase
activity (SB 431542) or with a siRNA for Smad-2/3, showed that CTGF
expression induced by TGF-b decreased to basal levels, indicating that
Smad-pathway was essential to TGF-b dependent expression of CTGF.
These studies suggest that CTGF expression induced by TGF-b is
modulated through a decorin dependent mechanism involving its
endocytic receptor LRP-1.
Supported by FONDAP, MIFAB, CARE, MDA 89419
IDENTIFICATION OF SOX9 BINDING SITE IN CCN2 (CTGF)
GENE BY USE OF ChIP ON CHIP ANALYSIS
Chundo Oh, Hideyo Yasuda and Benoit de Crombrugghe
Department of Genetics, University of Texas, M. D. Anderson Cancer
Center, Houston, TX 77030, USA
The transcription factor Sox9 is essential for several steps of the
chondrocyte differentiation pathway including chondrogenic mesen-
chymal condensation. To determine which genes upregulated during
chondrocyte differentiation are direct targets of Sox9, and to find out
the Sox9 binding site in the genes, we have performed chromatin
immunoprecipitation (ChIP) of chondrocytes using Sox9 antibodies.
The immunoprecipitated DNA was amplified and hybridized to a
custom-made high-density microarray, which covered a total 93 genes
from 15-kb 5’ to 10-kb 3’ of these genes with 50-mer oligonucleotides
containing 20 nucleotides overlap between oligos (ChIP on chip).
Several lines of evidence indicate that CCN2 (CTGF) enhances the
proliferation and maturation of chondrocytes. Therefore we added CCN2
gene in our ChIP on chip analyses supposing this might be a direct target
of Sox9. In the CCN2 gene, only one high affinity site was detected in its
promoterregionbyanti-Sox9- ChIPonchip,butnotbyconrtolIgGChIP
on chip. This site was detected in ChIP on chip analyses using both
sense–and anti-sense DNA as probe. In order to verify this Sox9 binding
site, we prepared several reporter constructs which have different length
of promoter region of CCN2. The sequence between −610 and −500
upstream from transcription start site is required for Sox9 to enhance the
promoter activity in a reporter assay. Further, the Sox9 binding site has
been confirmed by EMSA assay and ChIP experiment. These results
suggest that CCN2 (CTGF) is a direct target of Sox9 in chondrocytes and
should be regulated by it during chondrogenesis.
MECHANICAL REGULATION OF THE CYR61/CCN1
GENE REQUIRES THE COMBINED ACTIVITY
OF THE MYOCARDIN-RELATED TRANSCRIPTION FACTOR
(MRTF)—A AND P300/CBP IN SMOOTH MUSCLE CELLS
Jawaria Amir, Haibo Liu, Ada Lau and Brahim Chaqour
Department of Anatomy and Cell Biology, State University of New
York Downstate Medical Center, Brooklyn, New York, USA
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RhoA GTPase-dependent actin polymerization which essentially
controls the activation of transcription factors such as SRF. SRF
activity requires the relocalization of the SRF co-activator MRTF-A
from the cytoplasm to the nucleus and tethering SRF to CArG box
sequences. We hypothesized that both SRF and MRTF-A mediate
mechanical strain-induced Cyr61 gene expression.
The activity of a reporter construct containing 2,395 nucleotides
upstream the initiation start site of the human Cyr61 gene was
increased (up to 39-fold) by continuous cyclic stretching of smooth
muscle cells (SMCs). When the CArG box sequence for SRF binding
was mutated (CCAAA ➔ AGATC), the promoter activity was
significantly reduced (5.6-fold increase only) in mechanically stimu-
lated cells. Similarly, cotransfection with plasmid vectors expressing
dominant negative forms for either SRF or MRTF-A but not MRTF-B,
a structurally-related form of MRTF-A, significantly decreased the
Cyr61 promoter activity. The activity of the Cyr61 promoter reporter
was significantly reduced in SMCs isolated from MRTF-A -/- mice in
response to mechanical strain. Cells cultured from MRTF-A -/-
showed reduced adhesion points and stress fibers compared to cells
from wild type mice which is consistent with the important role of
MRTF-A in muscle fiber growth and maturation. MRTF-A, which was
shown to bind to unpolymerized actin (G-actin), was localized within
the cytoplasm in unstimulated cells and accumulate within the nucleus
in mechanically stimulated cells. Consistent with these results,
preincubation of the cells with inhibitors of actin polymerization such
as latrunculin B, or NTSMA, a cell-penetrating peptide containing the
N-terminal sequence Ac-EEED of smooth muscle -actin, that interfere
with actin polymerization, suppressed both nuclear translocation of
MRTF-A and Cyr61 promoter activation by cyclic stretch. Leptomycin
A, an inhibitor of nuclear export, induced nuclear accumulation of
MRTF-A but did not increase the Cyr61 promoter reporter gene activity
in unstimulated cells suggesting that (i) MRTF-A continuously shuttles
between cytoplasm and nucleus and (ii), nuclear localization of MRTF-
Awas not sufficient to activate the Cyr61 promoter. Interestingly, Cyr61
promoter activity was completely abolished by curcumin, a pharmaco-
logical inhibitor of p300/histone acetylase activity. Expression of p300
alone was insufficient to activate the Cyr61 promoter reporter but
augmented the promoter activity in the presence of leptomycin A. Co-
immunoprecipitation studies demonstrated direct interaction between
p300 and MRTF-A in mechanically stimulated cells. These studies
reveal that the combined activities of MRTF-A and p300 are involved in
the mechanical regulation of the Cyr61 gene.
PERIOSTIN IS EXPRESSED IN HUMAN SKIN
AND IS REGULATED BY MECHANICAL STRAIN
Weiyan Wen, Linda Jackson, Tom Daley, Andrew Leask,
and D. W. Hamilton
CIHR Group in Skeletal Development & Remodeling, Schulich School
of Medicine and Dentistry, Dental Sciences Building, University of
Western Ontario, London, Ontario, Canada. N6A 5C1
Periostin is a novel secreted matricellular protein with very diverse
functions that appear necessary for postnatal development in collagen-
rich tissues. The expression of periostin is most common in collagen-
rich connective tissues that are continually subject to mechanical
strains as a result of normal tissue function. We have recently
identified the presence of periostin protein in human skin, with the
protein localizing to the basement membrane, keratinocytes and
dermal fibroblasts. Furthermore, the skin of periostin knockout mice
is significantly thinner than their wild type counterparts, has reduced
collagen fibrillogenesis and cross-linking, which correlates with
reduced compliance in comparison with wild type mice. We
hypothesize that periostin is required for normal tissue homeostasis,
and will play a major role in cutaneous wound repair. To investigate
the control of periostin expression, fibroblasts were cultured on
collagen I under static conditions or 10% cyclic strain. Periostin
mRNA levels increased under cyclic loading, and showed a similar
expression pattern to thrombospondin-1 and collagen I. To assess if
culture matrix was a determinant of periostin expression, fibroblasts
were cultured under the same strain conditions, except on collagen IV.
Periostin expression increased 2 fold higher in fibroblasts on collagen
IV compared to those cultured on collagen I. To further examine
periostin expression, we utilized a punch wound cutaneous model in
C57Bl/6 mice. Wounds were assessed at 3, 7, and 21 days using
immunohistochemistry. Periostin expression was evident in granula-
tion tissue by day 3, and levels peaked at day 7. By day 21, periostin
expression declined to basal levels. We conclude that periostin
expression in normal skin may be regulated by mechanical strain,
and that periostin up-regulation in cutaneous wound repair is required
for remodeling of the extracellular matrix. Future experiments will
focus on assessing wound repair in periostin knockout mice, as well as
the “outside-in” signaling controlling periostin expression.
FUNCTIONAL AND BIOCHEMICAL ASSESSMENT OF CCN5
TARGETED TO THE NUCLEUS
Lan Wei, Joan Lemire, Cassandra Baughman, Kristina Cvitanovic,
Joshua Russo, Ronald Myers, Mark Gray, John J. Castellot, Jr.
Department of Anatomy and Cellular Biology, Tufts University
School of Medicine, Boston MA 02111, USA
Originally thought to exert its anti-proliferative effects through binding to
the cell surface, CCN5—like CCN3—has recently been detected in the
nucleus of cultured cells and in tissues. The role that nuclear CCN5 plays
in the nucleus and the mechanism regulating nuclear targeting are the foci
of our efforts. A CCN5 mRNA splice variant has been cloned from rat
ovary. This mRNA splice variant lacks exon 3, which encodes rat CCN5
IGFBP domain (I), and due to a shift of the opening reading frame
this splice variant produces a non-secreted truncated CCN5
containing only the VWC and TSP1 domains. While the full-
length CCN5 is only expressed in growth arrested SMC, the splice
variant is expressed in both growth arrested and exponentially
growing cells. To further investigate the subcellular localization
and potential function of CCN5 isoforms, we investigator con-
s t r u c t e das e r i e so fp l a s m i d se x p r e s s i n ge a c hd o m a i no fr a tC C N 5 ,
individually and in combinations. Additionally, each construct was
made in a secretable and non-secretable form, and tagged at both
the N-terminal and C-terminal ends with FLAG and Myc epitopes,
respectively. Using fluorescence microscopy, we simultaneously
analyzed N-terminal FLAG tag and C-terminal Myc tag in
transfected NIH 3T3, HEK293, C2C12, and COS7 cells. The
non-secreted forms of the VWC domain (V) alone, TSP1 domain
(T) alone, and IV, VT and IVT domain combinations are imported
into nucleus, whereas the same constructs containing an N-terminal
signal sequence are not detected in nucleus. Interestingly, the I
domain alone and the IT domain combination are never observed
in the nucleus, regardless of the presence or absence of a secretion
signal. We also tested an IVT construct of rat CCN5 that was
mutated at the only predicted nuclear localization sequence (NLS)
in the V domain. The mutant IVT construct was still capable of
importing into the nucleus in the cell lines tested above. Studies to
determine how these isoforms are targeted to the nucleus and
to assess their role in cell proliferation and motility are underway.
To complement the domain construct approach, we have also
developed several monoclonal antibodies directed against specific
domains of CCN5. They will be used in conjunction with other CCN5
Fifth international workshop on the CCN family of genes 103antibodies already available in our lab to analyze the expression
pattern of CCN5 isoforms in smooth muscle cells and in a variety of
cancers using tissue microarray. These studies should provide
important insights into the mechanism of action of CCN5.
POLY(ADP-RIBOSE) POLYMERASE-1 (PARP-1) AND PARP-1
BINDING ELEMENT (PBE) ENHANCE MURINE CCN2 GENE
TRANSCRIPTION IN PROXIMAL TUBULAR EPITHELIAL
CELLS (PTEC)
Tsutomu Inoue, Hiromichi Suzuki, Hirokazu Okada
Department of Nephrology, Saitama Medical University, Irumagun,
Saitama, Japan
Since we had found that PTEC expressed profibrotic protein CCN2 in the
fibrous kidney, we began to investigate the requirements for the epithelial
cell-selective induction of CCN2. Transient transfection experiments with
luciferase reporter minigenes bearing various fragments of the murine
CCN2 promoter region and cultured PTEC revealed that the −455 to −434
bp region contained novel, positive cis-elements for CCN2 gene
transcription. This 20 bp fragment bound to nuclear extracts from either
basal or TGFb-1-activated PTEC, and yielded a shifted band in the DNA
mobility shift assay. In addition, mutation in this 20 bp region lowered
CCN2promoteractivitiesinbasal aswell asTGFb-1-activatedPTEC(50%
and 30%, respectively) while mutation in either Smad binding element
(SBE) or basic control element-1 (BCE-1) in the CCN2 promoter lowered
them only in TGFb-1-activated PTEC (30%). These results suggested that
this 20 bp region enhances CCN2 gene transcription in basic and TGFb-1-
activated PTEC, and this 20 bp region and SBE as well as BCE-1 are
necessary for the full enhancement of CCN2 gene transcription in TGFb-1-
activated PTEC. By protein mass fingerprint analysis, we identified PARP-
1 as a trans-factor protein that binds to this 20 bp region. Our finding that
knocking-down of PARP-1 mRNA by antisense oligoDNA transfection,
but not treatment with a polyribosylation inhibitor, significantly decreased
CCN2 gene transcription in cultured PTEC suggested that PARP-1
enhances CCN2 gene transcription likely via its physical presence.
Therefore, we named this 20 bp cis-element as PBE. These machineries
were also found to be active in vivo since knocking-down of PARP-1
mRNA in PTEC significantly reduced levels of CCN2 mRNA and blocked
fibrogenesis in the kidney with ureter ligation. Thus, PARP-1 and PBE are
of importance for full induction of CCN2 gene transcription in PTEC by
TGFb-1, and likely to be targets for anti-fibrosis therapy since CCN2 is a
main mediator of profibrotic effects of TGFb-1 in the fibrous kidney.
ROLES OF CCN2 IN SKELETAL GROWTH
AND REGENERATION—REQUIREMENT
FOR BOTH ENDOCHONDRAL AND INTRAMEMBRANOUS
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Using mainly in vitro system, we have shown that CCN2, which is
highly expressed in (pre)hypertrophic chondrocytes, plays an impor-
tant role in endochondral ossification by acting on chondrocytes,
osteoblasts and endothelial cells. To confirm these in vitro findings in
vivo, we generated transgenic mice (tg) overexpressing the ccn2 gene
in cartilage under the control of the type II collagen (Col2a1)
promoter. As a result, the body size of tg mice was enlarged owing
to prolonged diaphyses of long bones, corresponding to the over-
expression level of ccn2 mRNA. Supporting these results, cultured
chondrocytes isolated from tg mice expressed enhanced levels of
col2a1, col10a1, and aggrecan mRNA and showed increased
accumulation of proteoglycans. A histochemical analysis of tibia from
17.5E and P1 revealed that the deposition of proteoglycans and type II
collagen increased in transgenic cartilage. Micromass cultures pre-
pared from tg E11.5 limb bud cells showed accelerated cartilaginous
nodule formation in comparison to wt limb bud cells, indicating
stimulation of chondrogenesis by overexpressed CCN2. Furthermore,
expression of vascular invasion factors such as vegf and mmp9 mRNA
was also enhanced. In addition, cell proliferation in the resting and
proliferative zone of cartilage was increased, and enhanced apoptosis
in the zone of cartilage-bone transition was observed. Moreover, bone
mineral contents and thickness of cortical bone were increased in tg
mice. These findings indicate that overexpression of CCN2 in
cartilage accelerates endochondral ossification by promoting prolifer-
ation and initial to terminal differentiation of chondrocytes, resulting
in prolonged long bones.
In contrast to endochondral ossification, little is known concerning
the role of CCN2 during intramembranous bone formation. To
investigate the role of CCN2 in intramembranous bone development,
a comparative analysis of wild-type and Ccn2 null mice was conducted.
Multiple histochemical methods were employed to analyze the effects of
CCN2 deletion in vivo and effects of CCN2 on the osteogenic response
were evaluated with the isolated and cultured osteoblasts. As a result,
we found a drastic reduction of the osteoblastic phenotype in Ccn2 null
mutants. Importantly, addition of exogenous CCN2 promoted every step
of osteoblast differentiation and rescued the attenuated activities of the
Ccn2 null osteoblasts. These results suggest that CCN2 is also required
for the normal intramembranous bone development.
In addition to normal skeletal development, administration of CCN2-
gelatin hydrogel complex together with collagen scaffold to artificial
bone defect of rat model revealed an important role of CCN2 in skeletal
regeneration.
SKELETAL PHENOTYPE IN TRANSGENIC MICE
OVER-EXPRESSING CTGF IN CELLS OF THE OSTEOBLAST
LINEAGE
Fayez F. Safadi
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CTGF has recently emerged as an important growth factor in
osteogenesis, demonstrated by its ability to promote proliferation,
matrix production and differentiation in cultures of osteoblasts.
Since most of the data concerning the role of CTGF in
osteogenesis has come from in vitro studies, in this study we
generated transgenic mice in which CTGF is over-expressed under
control of the truncated 3.6 kb collagen type 1 (pOBCol3.6)
promoter (CTGF
pOBCol3.6 mice). This promoter was chosen because
it is expressed early during osteoblast differentiation. The targeting
vector used to generate transgenic mice also contained LacZ (to
identify cells expressing the transgene) and an enhancer element to
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by PCR of tail DNA using transgene specific primers. Six lines were
established by mating founder mice with C57/Blk6 wild type (WT)
mice. Multiple tissues were used to examine specificity of transgene
expression using PCR with transgene specific primers, followed by
confirmation of CTGF mRNA expression levels by Northern blot
analysis. Transgene expression was highest in long bone and calvaria,
with lower levels of expression in other type I collagen producing
tissues (lung and skin). Two of the transgenic lines with different CTGF
expression levels were used for analysis of the skeletal phenotype. Mice
from one line survive, however, mice from the other line die within a
few days after birth. Line one showed a 3-4 fold (moderate expression)
increase and line two showed a >7-8 fold (high expression) increase in
CTGF protein levels in bone when compared to age matched WT mice.
Histological and morphometric examination of the distal femoral
metaphysis from TG mice with moderate over-expression of CTGF
exhibited significant increases in trabecular bone volume associated
with increased osteoid thickness and osteoblast activity/numbers
compared to WT mice. Increased thickness of the periosteum with
increased numbers of osteoprogenitor cells was also observed in TG
compared to WT bone. Primary cultures of osteoblasts derived from
these TG mice also exhibited enhanced differentiation (ALP staining
and mineralization) compared to WTcultures. Surprisingly, examination
of bones from transgenic mice over-expressing CTGF at very high
levels demonstrated an increase in osteoclast number and size. These
data suggest that the precise effects of CTGF on bone cell differentiation
and function depend on the magnitude of CTGF over-expression.
Moderate levels of CTGF have a direct effect on osteoblasts to promote
bone formation, while high levels favor the formation of osteoclasts,
perhaps indirectly through a RANK-L dependent mechanism.
CCN1 AND CCN2 ARE ESSENTIAL FOR CHONDROGENESIS
Faith Hall-Glenn*, Andrea De Young*, Eric Sarcassian and Karen Lyons
* these authors contributed equally to this analysis
Department of Molecular, Cell and Developmental Biology
Department of Orthopaedic Surgery, David Geffen School of Medicine
The University of California, Los Angeles, Los Angeles, CA, USA
CCN1 (Cyr61) and CCN2 (CTGF) are essential for many aspects of
development. CCN1 is a potent angiogenic factor and its global
deletion results in early embryonic lethality due to defects in
angiogenesis and vasculogenesis. CCN1 null mice display defects in
Integrin-mediated cellular adhesion and in the matrix production that
induces this adhesion. A global deletion of CCN2 results in perinatal
lethality due to improper chondrogenesis. Ccn2 null defects are attributed
to impaired hypertrophic chondrocyte proliferation, extracellular matrix
production and vascularization. Both CCN1 and CCN2 regulate specific
aspects of angiogenesis and bone formation in vivo. However, the role of
CCN1 in chondrogenesis in vivo is unknown, nor is it established whether
CCN1 and CCN2 have overlapping functions in skeletal development.
We have generated mice lacking both CCN1 and CCN2 specifically in
cartilage to address these issues. Cartilage specific loss of CCN1 leads to
perinatal lethality, but the skeletons of Ccn1
CKO (CKO = cartilage-specific
knockout) mice exhibit only minor alterations. However, Ccn1/Ccn2
double mutants exhibit perinatal lethality and a skeletal phenotype that is
more severe than that of Ccn1 and Ccn2 null mice. Ccn1/Ccn2 double
mutants display global chondrodysplasia. The growth plates of double
mutants exhibit an expansion of the hypertrophic zone and a decrease in
trabecular and perichondrial bone formation, which is indicative of defects
in chondrocyte differentiation, clearance and vascular invasion. Com-
bined, this evidence demonstrates that CCN2 is required for chondro-
genesis and that there is functional overlap between CCN1and CCN2 in
endochondral bone formation.
CCN3 AND NOTCH/BMP SIGNALS
Ken-ichi Katsube
Oral Pathology, Graduate School of Tokyo Medical and Dental
University Yushima, Bunkyo-ku, Tokyo Japan
CCN3 inhibitory effect on osteogenesis has been reported from many
groups and the recent reports using transgenic mice (gain/loss of function)
strongly confirmed it from the aspect of body formation. CCN3 effect is
believed to relate to several different signal cascades such as BMP, Wnt or
Notch, but still the priority of the used signals is unclear. The group of
Canalis concluded the BMP signal has the priority among these signals, but
our results demonstrated the importance of Notch signal. To investigate
these molecular talks, we constructed deletion forms of CCN3 and
transfected to Kusa-A1, a mouse osteogenic mesenchymal stem cell line.
A CT domain deleted form (delCT) has shown a decreased osteogenic
activity, but did not change the neurogenic activity. Previously, we
confirmed that CT domain is responsible for Notch interaction, but not
for CCN3 dimerization. Therefore, it was possible to hypothesize that the
reduction of osteogenesis might be due to the deceased Notch activity. But
we evaluated downstreams of Notch signal and verified that Hey1
expression was attenuated by delCT transfection. We also demonstrated
that delCTstill possessed the BMP binding activity, indicating its masking
effect. In fact, delCT showed a decreased phosphorylation of SMAD
proteins when transfected. CCN3 expression has been investigated in
osteoblast cell lines in other groups, but we employed a bone marrow-
derived mesenchymal stem cell line, which naturally expresses CCN3. We
conclude that inhibitory effect of CCN3 against osteogenesis is commu-
nicated by both Notch and BMP signals.
FAK/SRC SUPPRESSES EARLY CHONDROGENESIS:
CENTRAL ROLE OF CCN2
Daphne Pala, Mohit Kapoor, Anita Woods, Karen Lyons,
David E. Carter, Frank Beier and Andrew Leask
Department of Physiology and Pharmacology, Schulich School of
Medicine and Dentistry, University of Western Ontario, London, ON,
Canada N6A 5C1
Departments of Biological Chemistry and Orthopedic Surgery,
University of California, Los Angeles, CA, 90095, USA
Adhesive signaling plays a key role in cellular differentiation, including
in chondrogenesis. Herein, we probe the contribution to early chondro-
genesis of two key modulators of adhesion, namely FAK/src and CCN2
(Connective tissue growth factor, CTGF). We use the micromass model
of chondrogenesis to show that FAK/src signaling, which mediates cell/
matrix attachment, suppresses early chondrogenesis including the
induction of Ccn2, Agc and Sox6. The FAK/src inhibitor PP2 elevates
Ccn2, Agc and Sox6 expression in wild-type mesenchymal cells in
micromass culture, but not in cells lacking CCN2. Our results suggest a
critical feature permitting chondrogenic differentiation is a reduction in
FAK/src signaling, and that CCN2 operates downstream of this loss to
promote chondrogenesis.
CTGF/CCN-2 IS PRODUCED BY NON-CHONDRODY-
STROPHIC CANINE INTERVERTEBRAL DISC-DERIVED
NOTOCHORDAL CELLS AND UPREGULATE NUCLEUS
PULPOSUS AGGRECAN GENE EXPRESSION
W. Mark Erwin*, Keith Ashman
#, Paul O’Donnell
#, Robert Inman^
*Division of Orthopaedic Surgery,
^Department of Medicine and
Immunology, Toronto Western Hospital,
#Samuel Lunenfeld Research
Institute, Mt. Sinai Hospital
Fifth international workshop on the CCN family of genes 105Non-chondrodystrophic (NCD) dogs maintain large populations of
notochord cells within their intervertebral discs for many years and are
not known to develop degenerative disc disease until much later in
life. Chondrodystrophic breeds develop disc disease much earlier and
they have a paucity of such notochord cells. We have previously
reported upregulation of aggrecan, versican and hyaluronic acid
synthase-2 genes as a consequence of treatment of nucleus pulposus
cells treated with notochordal cell conditioned medium. We were the
first to demonstrate that notochordal cells secrete connective tissue
growth factor (CTGF/CCN-2). CCN-2 has been shown to stimulate
healing of defects in articular cartilage and has been hypothesized to
be of potential utility in the treatment of damage to articular cartilage.
Since we have identified the presence of CCN-2 in NCCM, we chose
to examine aggrecan gene expression as a function of culturing bovine
intervertebral disc-derived chondrocytes with known doses of recom-
binant human CTGF as well as NCCM and minimal media devoid of
anabolic substances (DMEM). Further, we have demonstrated the
presence of CTGF in notochordal cell lystates using Western blotting
methods.
Herewedemonstratethatcaninenotochordcells(obtainedfromNCD
dogs) were cultured within alginate beads in serum-deficient conditions
(DMEM) to produce notochord cell conditioned medium (NCCM).
Bovine disc-derived chondrocytes were obtained and cultured for 3 days
in totally serum-free medium and then cultured for 24 h with DMEM,
NCCMandDMEM+dosesof50,100,and200ng/mLaswellasNCCM
+ 200 ng/mL of recombinant human CTGF (rCTGF or rCCN-2). After
24 h, total RNAwas extracted (Trizol) from the chondrocytes, the RNA
was quantified at OD260/280 and then 1 μg total RNA was reverse
transcribed. The resulting cDNA obtained was subjected to semi-
quantitative RT-PCR using aggrecan specific primers.
We demonstrated that aggrecan gene expression was modestly
produced in the chondrocytes treated with DMEM only however in a
dose-dependent relationship aggrecan gene expression was robustly
increased by rCTGF and NCCM as compared to DMEM. NCCM
induced chondrocyte aggrecan gene expression at a similar level to
between 100 and 200 ng/mL rCTGF. NCCM +200 ng/mL CTGF
resulted in similar upregulation of aggrecan as 200 ng/mL alone.
CCN2 IS REQUIRED FOR VASCULAR REMODELING IN VIVO
R. Andrea de Young, Luisa Iruela-Aripse, and Karen M. Lyons
Department of Molecular, Cell and Developmental Biology
Department of Orthopaedic Surgery, David Geffen School of Medicine
The University of California, Los Angeles, Los Angeles, CA, USA
Numerous in vitro studies have demonstrated that CCN2 regulates
angiogenesis. However, both pro-and anti-angiogenic effects have
been reported. Hence, we examined Ctgf-/- mice as well as mice
lacking Ccn2 specifically in endothelial cells for angiogenic
phenotypes. This analysis revealed that the vascular system develops
normally initially in Ccn2-/- mice, but vascular remodeling is
defective. Analysis of endothelial-specific Ccn2 knockouts, gener-
ated using VE-CAD-Cre, showed that the vascular defects are due to
loss of Ccn2 in endothelial cells. Moreover, the endothelial-specific
knockout mice die perinatally, demonstrating that Ccn2 is required
for vasculogenesis in vivo. Histological analysis reveals that the
vascular defect is caused by insufficient pericyte recruitment and
stabilization of endothelial-pericyte interactions. Furthermore, the
defect in pericyte recruitment is related to a defect in endothelial cell
shape; in mutants, endothelial cells are tortuous and exhibit
numerous abluminal protrusions. Electron microscopy confirmed
this hypothesis, and revealed that endothelial basement membranes
are abnormal in Ccn2-/- mice. Analysis of specific ECM components
revealed that the major components of basement membranes are
expressed at normal levels in Ccn2 mutants, but that their assembly
into a cohesive basement membrane is defective. These results
reveal an essential for CCN2 in basement membrane assembly, and
raise the possibility that CCN2 is an essential regulator of epithelial-
mesenchymal interactions and maintenance of stem cell niches that
involve basement membranes.
KLF15 REGULATES THE CARDIAC RESPONSE TO STRESS
Mukesh Jain
Case Cardiovascular Research Institute, Case Western Reserve University
Cardiac hypertrophy and fibrosis is a common response to injury and
hemodynamic stress and an important harbinger of heart failure and
death. Herein, we identify the Kruppel-like factor 15 (KLF15) as a novel
regulator of the heart’s response to stress. KLF15 is expressed in both
cardiomyocytes and fibroblasts. KLF15 expression is reduced by a broad
spectrum of pro-hypertrophic agents in cardiomyocytes (phenylephrine,
Tgfb1, Ang II) and pro-fibrotic agents (Tgfb1, Ang II). Consistent with
this observation, myocardial expression of KLF15 is reduced in rodent
models of hypertrophy and in biopsy samples from patients with
pressure-overload induced by chronic valvular aortic stenosis.
Studies in cardiomyocytes indicate that sustained expression of
KLF15 in neonatal rat ventricular cardiomyocytes (NRVMs) inhibits cell
size, protein synthesis and hypertrophic gene expression. Mechanistical-
ly, a combination of promoter analyses (ANF and BNP) and gel-shift
studies suggest that KLF15 can inhibit GATA4 and MEF2 function.
Studies in neonatal rat ventricular fibroblasts (NRVFs) indicate that
sustained expression of KLF15 inhibited basal and TGFb1-induced
CTGF expression—a key regulator of tissue fibrosis. To determine the
molecularbasis forKLF15’sabilitytoinhibitCTGFexpression,promoter
analyses were undertaken. KLF15 inhibited basal and TGFb1-mediated
induction of the CTGF promoter activities. Previous studies indicate that
TGFb1-mediated induction of CTGF occurs via Smad3 as well as via the
co-activator P/CAF. Using a combination of ChIP and electrophoretic
mobility shift assays, we show that that while KLF15 has no significant
effect on Smad3 binding to CTGF promoter, it strongly inhibits
recruitment of P/CAF to CTGF promoter. Consistent with this observa-
tion,KLF15mediatedinhibitionofCTGFwasrescuedbyoverexpression
of P/CAF.
ToelucidatetheroleofKLF15incardiacbiologyinvivo,KLF15-null
mice were generated. KLF15-null mice are viable but, in response to
pressure overload, develop an eccentric form of cardiac hypertrophy
characterized by increased heart weight, exaggerated expression of
hypertrophic genes (ANF, BNP), left ventricular cavity dilatation with
increased myocyte size and reduced left ventricular systolic function.
Furthermore, hearts from KLF15 (-/-) mice subjected to aortic banding
exhibited increased CTGF levels. Trichrome staining also suggested
elevateddepositionofcollagenproteininKLF15(-/-)heartinresponseto
mechanical stress. These data identify KLF15 as part of a heretofore
unrecognized pathway regulating the cardiac response to hemodynamic
stress.
THE ROLE OF CTGF IN PAEDIATRIC ACUTE
LYMPHOBLASTIC LEUKAEMIA
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106 Fifth international workshop on the CCN family of genesAcute lymphoblastic leukaemia (ALL) is the most common form of
cancer in children. It is a heterogenous disease, initiated by a range of
genetic events that give rise to multiple clinical subtypes with varying
prognoses. Although survival rates are approaching 80%, a significant
number ofpatientscontinuetorelapse andtheoutlook fortheseisdismal.
In order to improve outcome novel therapeutic strategies are required.
Leukaemias arise in the haemopoietic cells of the bone marrow and this
microenvironment plays a major role in the disease. Using microarray
technology we compared the gene expression profile of ALL to normal
CD34
+ cells separated from bone marrow, and we identified a set of
highly differentially expressed genes. Many of the top-ranked genes are
known to mediate cell–cell interactions, including ECM1, EFNB2,
BMP2 and CTGF. Four independent studies on B-lineage ALL in
paediatric and adult patients showed that 75% of specimens consistently
expressed CTGF at very high levels. In our paediatric patient specimens
the gene was expressed over a wide range, from 2.3–to 380-fold by
array measurement. Our current studies focus on the mechanisms
leading to high CTGF expression. In order to gain insight into the role
of CTGF in leukaemia we studied ALL cell lines established from
paediatric patients and demonstrated secreted CTGF of 30 kDa and
38 kDa, however the proliferation of ALL cells was not enhanced in the
presence of recombinant human (rh) CTGF. In contrast, bone marrow
stromal cells showed a dose-dependent proliferative response to
rhCTGF, suggesting that a paracrine mechanism may be involved. We
examined the gene expression of bone marrow stromal cells incubated
with rhCTGF and identified prominent signatures implicated in the
regulation of cell–cell interactions and proliferation. In order to test
strong adhesion (against gravity) we designed a closed culture system
and monitored adhesion by flow cytometry under various experimental
conditions. The presence of rhCTGF mediated enhanced adhesion of
ALL cells. Our current studies focus on the functional role of the
signalling molecules implicated by our studies, including resistance to
drug therapy. Activation and secretion of CTGF play a prominent role in
ALL, leading to modified interactions with the microenvironment, and
these processes are thought to promote the growth of pre-leukaemic
cells. Improved understanding of the CTGF-mediated changes in pre-
malignant and malignant cells in the bone marrow microenvironment is
expected to lead to better therapeutic strategies for patients with ALL.
EXPRESSION OF CCN PROTEINS IN NORMAL HUMAN
SKIN IN VIVO AND AFTER WOUND HEALING
Laure Rittié
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CCN proteins have emerged as important and ubiquitous modulators of
development and adult organ function. To date, CCN protein distribution
and function in adult human skin has not been carefully examined. Human
skin is comprised of multiple cell types of ectodermal, mesodermal, or
neural-crest origin. In this study, we examined localization and expression
of the six CCN proteins in normal adult human skin and during early stages
of wound healing in vivo, in both dermal and epidermal compartments of
the skin. Transcript and protein expression were studied by laser-capture
microdissection-coupled real-time RT-PCR and immunohistochemistry,
respectively. First, we studied normal human skin to determine
localization and expression levels of CCN proteins. Our results
demonstrate that among the six CCN proteins, CCN2, CCN3, and
CCN5 were most highly expressed in the epidermis. CCN3 and CCN5
proteins were most prominent in epidermal keratinocytes, whereas CCN2
was primarily expressed by melanocytes. Differential expression within
epidermal layers suggests that CCN3 and CCN5 are linked with
keratinocyte differentiation. CCN2 and CCN5 mRNA were the most
highly expressed in the dermis. CCN3 mRNA was ~3 fold lower than
CCN2/5, CCN1/4/6 transcripts were expressed at similar levels, which
were approximately 200-fold lower than those of CCN2/5. Next, we
studied alterations of CCN mRNA and protein expression during
reepithelialization and dermal remodeling, following skin wounding.
Wounding was accomplished by thermal ablation of the epidermis of
normal forearm skin, by CO2 laser. Our data show that, in addition to
being spatially regulated, CCN proteins are temporally and specifically
regulated during different phases (inflammation, proliferation, and
remodeling) of wound healing. CCN1 and CCN4 expression gradually
increased, while CCN5 decreased, in the dermis during the first week of
wound healing. CCN1 was localized to blood vessels. CCN2 increased
in the dermis during later stages of remodeling, in association with
deposition of new extracellular matrix. In contrast, CCN3 expression
was substantially decreased in epidermis and dermis during the phase of
intense cellular proliferation. CCN6, expressed at low levels in adult
human skin, was not altered during wound healing. Taken together,
these data demonstrate cell type specific expression of CCN proteins in
human skin, and stage-dependent regulation during wound healing.
These data suggest that CNN family members exert distinct functional
roles in the epidermis and dermis of human skin in vivo.
CONNECTIVE TISSUE GROWTH FACTOR PROMOTER
ACTIVITY IN NORMAL AND WOUNDED SKIN
Mohit Kapoor, Shangxi Liu, Kun Huh, Sunil Parapuram,
Laura Kennedy and Andrew Leask
CIHR Group in Skeletal Development and Remodeling, Division of
Oral Biology and Department of Physiology and Pharmacology,
Schulich School of Medicine and Dentistry, Dental Sciences Building,
University of Western Ontario, London ON, Canada, N6A 5C1
In skin, connective tissue growth factor (CTGF/CCN2) is induced during
tissue repair. However, the exact cell types in which CCN2 is expressed in
normal and wounded skin remains controversial. In this report, we use
transgenic knock-in mice in which the Pacific Jellyfish Aequorea victoria
gene enhanced green fluorescent protein (E-GFP) is inserted between the
endogenous CCN2 promoter and gene. Unwounded (day 0) and wounded
(days 3 and 7) skin was examined for GFP (to detect cells in which the
CCN2 promoter was active), a—smooth muscle actin (a-SMA) (to detect
myofibroblasts), and NG2 (to detect pericytes) expression. In unwounded
mice, CCN2 expression was absent in epidermis and was present in few
cells in the dermis. Upon wounding, CTGF was induced in the dermis.
Double-immunolabeling revealed that CCN2-expressing cells also
expressed a-SMA, indicating CCN2 was expressed in myofibroblasts. A
subset (~30%) of myofibroblasts was also NG2-positive, indicating that
pericytes significantly contributed to the number of myofibroblasts in the
wound. Pericytes expressed CCN2. Collectively, these results indicate that
CCN2 expression in the skin correlates with myofibroblast induction, and
that CCN2-expressing pericytes are significant contributors to myofibro-
blast activity during cutaneous tissue repair.
ULTRAVIOLET IRRADIATION INDUCES CYR61/CCN1,
A NOVEL MEDIATOR OF COLLAGEN HOMEOSTASIS,
VIA ACTIVATION OF TRANSCRIPTION FACTOR AP-1
IN HUMAN SKIN FIBROBLASTS
Taihao Quan, Zhaoping Qin, Yuan Shao, Yiru Xu, Sewon Kang,
John J. Voorhees, Gary J. Fisher
Department of Dermatology, University of Michigan Medical School,
Ann Arbor, Michigan, USA
Fifth international workshop on the CCN family of genes 107Ultraviolet (UV) radiation from the sun damages skin connective tissue
dermis andcauses premature skinaging (photoaging). This photodamaged
skin is largely caused by imbalance of collagen homeostasis, characterized
by elevated production of collagen-degrading matrix metalloproteinases
(MMP) and reduced production of new collagen. This aberrant dermal
collagen homeostasis is mediated in part by CCN family member,
cysteine-rich protein 61 (CYR61/CCN1). CYR61 functions as a novel
mediator of collagen homeostasis by inhibiting type I collagen production,
the major structural protein in human skin, and promoting its degradation.
CYR61 is significantly elevated in the dermis of photoaged human skin,
acutely UV-irradiated human skin in vivo, and UV-irradiated human skin
fibroblasts. Inhibition of UV-induced CYR61 by CYR61 siRNA
significantly attenuated UV-induced inhibition of type I procollagen and
up-regulation of matrix metalloproteinase-1 (MMP-1), indicating CYR61
functions as a novel mediator for UV-induced aberrant collagen
homeostasis. UV irradiation significantly activates CYR61 promoter
without changing the stability of CYR61 mRNA and protein, indicating
the primary mechanism of CYR61 induction by UV irradiation is
transcriptional. Analysis of CYR61 promoter revealed that CYR61
proximal promoter contains functional AP-1 binding site. Analysis of
proteins bound to the AP-1 site revealed that UV irradiation increased
bindingofAP-1family members,c-Junandc-Fos.Deletionormutationof
AP-1 binding site in the CYR61 promoter near completely abolished UV
activation of CYR61 promoter. Furthermore, functional blocking of c-Jun
or knockdown c-Jun substantially reduced UV-induced activation of
CYR61 promoter and CYR61 expression. These data demonstrate that
CYR61 is transcriptionally regulated by UV irradiation via activation of
transcription factor AP-1, and functions as a novel mediator for solar UV
radiation-induced dermal connective tissue damage.
THE INTERACTION OF β-CATENIN
WITH EXTRA-CELLULAR MATRIX COMPONENTS
IN DERMAL FIBROBLASTS DURING
WOUND HEALING
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During cutaneous wound healing, dermal fibroblasts synthesize new
extracellular matrix (ECM) to repair the skin. CCN family members
(most notably CCN2, also called connective tissue growth factor) play a
role in this process. β-catenin binds and stimulates tcf transcription
factors, and it is activated in wound fibroblasts. However, the factors that
regulate β-catenin during healing, and its transcriptional targets are not
wellunderstood.One possibilityisthe involvement ofthe ECM as both a
target and a regulator of β-catenin activity. We are investigating the
existence of a reciprocal regulatory loop between β-catenin and ECM
during healing. The expression pattern of several ECM components,
which include β-catenin transcriptional targets, was verified using real
time PCR analysis in mouse full thickness wounds. To investigate the
effect of ECM on β-catenin, primary dermal fibroblasts from tcf-reporter
mice were cultured on collagen I, IV, fibronectin, and matrigel. We found
an increase in activated β-catenin protein and in tcf-dependent
transcription compared to plastic. Inhibition of glycogen synthase kinase
3β, which mediates the destruction of β-catenin, was demonstrated in
fibroblasts grown on ECM. The common ECM-integrin binding motif,
RGDS, which activates integrins that also interact with CCN2, caused an
elevation in active β-catenin protein. This was examined in vivo using
fibronectin deficient mice, in which a higher level of β-catenin was
observed during wound repair. To identify ECM-associated targets of β-
catenin during wound healing, we are using expression array analysis to
compare gene expression in mice with conditionally regulated β-catenin
versus ‘wild-type’ levels. Our results to date suggest that numerous
ECM and adhesion molecules are differentially expressed in the wounds
of mice with conditionally stabilized β-catenin compared to ‘normal’
wounds. Thus, ECM upregulates β-catenin protein and transcriptional
activity and β-catenin modulates the expression of ECM components,
suggesting that the ECM acts in a feedback loop during wound repair to
regulate β-catenin. Elucidating the mechanism of interaction between
β-catenin and the ECM during healing may generate new therapies to
treat wound healing disorders.
THE ROLE OF THE MATRICELLULAR PROTEIN DEL1
IN BONE FRACTURE HEALING
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DEL1 is a 52 kDa secreted, extracellular matrix-associated protein
whose structure is notable for three EGF-like repeats, two discoidin-
like domains, and an RGD motif. The protein has been shown to bind
integrins avb3 and avb5, and to induce angiogenesis in in vitro assays.
During development, Del1 mRNA is expressed in developing vascular
structures. We have found very prominent Del1 expression in
cartilaginous tissues. Expression can be seen in hypertrophic cartilage
as well as mature cartilage. These data about DEL1’s biochemistry
and developmental pattern of expression are strikingly similar to
published data on CYR61 (CCN1) and CTGF (CCN2) raising
questions about their in vivo biological role.
Transgenic DEL1 null mutant mice appear normal, are of equal size
to wild type littermates, and are fertile. Litters from heterozygote parents
show expected Mendelian ratios suggesting there is no effect on
embryonic viability. Skeletal dissections and radiographs did not reveal
any obvious abnormalities in null mutant mice. Using a tibial fracture
model, we detected decreased bony callus formed in the null mutant
mice compared to wild type littermates using radiographs and microCT.
Using purified DEL1, we found it to be a potent inhibitor of
apoptosis induced through either intrinsic or extrinsic pathways in
primary chondrocytes with no effect on chondrocyte proliferation.
Inhibition of apoptosis was through integrin binding and required
the RGD motif. Using antibodies that blocked binding to specific
integrins, we found that inhibition of apoptosis requires binding to
integrin avb5, but not avb3. The anti-apoptotic effect of Del1 was
not blocked by soluble proteoglycans including heparin, chondroi-
tin and dermatan suggesting that proteoglycans are not required as
co-factors in binding.
Bone forms during development through endochondral ossification
in the majority of the skeleton, except in the skull plates where
membranous ossification takes place. During endochondral ossification,
bone forms through an intermediate of hypertrophic cartilage whereas
there is no cartilaginous intermediate in membranous bone formation. In
our fracture model, fracture healing occurs through endochondral
ossification. We propose that Del1 acts to prevent premature apoptosis
of the hypertrophic cartilage in the fracture callus leading to more robust
bone formation. These findings are of interest in comparisons with
CYR61 and CTGF null mutants phenotypes, and suggest that despite
similar receptors and in vitro activity, additional factors are at play in
determining the in vivo biological role.
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The degree of differentiation of mammary epithelial cells is dependent on
their response to basement membrane and stromal protein-induced signals.
Our previous work determined that connective tissue growth factor
(CTGF/CCN2), a known stromal mediator, was highly up-regulated
during lactogenic differentiation of mouse mammary epithelial cells.
CTGF/CCN2 is transcriptionally regulated by dexamethasone, and is
required for lactogenic differentiation of the HC11 mouse mammary
epithelial cell line. Using a CTGF/CCN2 Tet-off system in the HC11 cell
background, elevated CTGF/CCN2 expression enhanced multiple
markers of lactogenic differentiation including β-casein transcription,
mammosphere formation, and stabilization of Stat5 phosphorylation.
Infection of primary mouse mammary epithelial cells with replication
defective adenovirus encoding CTGF/CCN2 induced similar responses.
Elevated CTGF/CCN2 expression decreased the requirement for extracel-
lular matrix components including collagen I, fibronectin, and laminin for
initiation of β-casein transcription. Because β1 integrin signaling is
requiredforlactogenic differentiationand the transcriptionof β-casein, the
contribution of CTGF/CCN2 expression to the formation and stability of
the β-casein promoter transcription complex has been examined by
chromatin immune-precipitation (ChIP). The effect of CTGF/CCN2 on
both Stat5 and the SWI-family protein, Brg1, binding and function at the
b-casein promoter will be reported.
CTGF/CCN2 expression both enhanced cell growth and survival
and prevented apoptosis of mammary epithelial cells. HC11 cells
expressing CTGF/CCN2 exhibited an increase in the level of β1
integrin and downstream survival signaling mediators including
phospho-FAK, phospho-Akt, and cyclin D1. Elevated CTGF/CCN2
levels increased the formation of focal adhesion complexes, as viewed
by immunofluorescence, and increased expression levels of focal
adhesion-related adaptor, structural, and signaling proteins including
parvin, p130cas, paxillin, Src, vinculin, and integrin-linked kinase.
These results demonstrate that the mechanism by which CTGF/CCN2
contributes to lactogenic differentiation is via activation of β1
integrin-mediated adhesion complexes and integrin-dependent signal-
ing pathways.
CCN2/CTGF–CARDIOPROTECTIVE FACTOR
IN MYOCARDIAL ISCHEMIA/REPERFUSION INJURY
AND HEART FAILURE
M. Shakil Ahmed, Jørgen A. Gravning, Vladimir N. Martinov,
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Background: In physiologic postnatal life expression of myocardial
CTGF/CCN2 is repressed. However, myocardial CTGF is dramat-
ically induced in heart failure. Yet, the physiologic and patho-
physiologic roles of myocardial CTGF remain unresolved.
Methods and Results: To elucidate the actions of myocardial
CTGF and its putative role in heart failure, transgenic mice with
cardiac-restricted (α-MHC promoter) overexpression of CTGF
were generated. Transgenic CTGF (Tg-CTGF) mice had slightly
smaller cardiac mass than that non-transgenic littermate controls
(NLC) (heart weight/body weight ratio; 4.5±0.1 vs. 5.2±0.1 mg/g
in Tg-CTGF vs. NLC, p<0.05). Consistently, echocardiography
revealed slightly smaller left ventricular (LV) dimensions in Tg-
CTGF vs. NLC mice. Simultaneous LV pressure-volume analysis in
vivo did not disclose significant alterations of contractility and
cardiac output, or evidence of left ventricular dysfunction in Tg-
CTGF mice. Analysis of myocardial gene expression by DNA
microarray revealed a gene expression signature of Tg-CTGF mice
consistent with inhibition of myocardial growth, and activation of
genes that confers cardioprotection towards ischemia/reperfusion
injury, as well as activation of genes that encode extracellular matrix
proteins. In order to test the functional significance of these gene
expression signatures in cardiac pathophysiology, hearts from Tg-
CTGF and NLC mice were subjected Langendorff perfusion ex vivo
and 40 min of global ischemia succeeded by 60 min of reperfusion.
Infarct size was markedly diminished in Tg-CTGF vs. NLC hearts
and recovery of LV developed pressure was enhanced. Consistently,
recombinant hCTGF included in the perfusion buffer prior to
ischemia also conferred cardioprotection and diminished infarct
size. Tg-CTGF mice subjected to pressure-overload by abdominal
aortic banding displayed diminished hypertrophy and preserved LV
pressure-volume relations after 12 weeks compared with NLC mice
subjected to similar aortic constriction.
Conclusion: This study discloses the novel findings that CTGF
exerts antihypertrophic actions in the heart, delays onset of heart
failure following aortic constriction, and confers cardioprotection
by preemptive preconditioning due activation of salvage kinase
signaling pathways and reprogramming of gene expression.
HIGH GLUCOSE AND FREE FATTY ACID ADVERSE
EFFECTS ON CARDIAC MYOCYTES ARE MEDIATED
BY CCN2/CONNECTIVE TISSUE GROWTH FACTOR
(CTGF) THROUGH TrkA
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Diabetic cardiomyopathy is characterised by interstitial fibrosis,
cardiomyocyte hypertrophy and apoptosis. CCN2, also known as
CTGF, is implicated in the fibrosis however whether it contributes to
the cardiomyocyte changes, or to documented adverse effects of high
glucose and lipids on these cells, remains unknown.
H9C2 cardiomyocytes were treated with recombinant human (rh)
CTGF, high glucose or the saturated fatty acid, palmitate. Each
reagent induced cell hypertrophy, as indicated by the ratio of total
protein /cell number and the gene expression of cardiac hypertrophy
marker genes ANP and α-skeletal actin, by qRT-PCR. Data shown are
at 24 h and similar effects occurred at 48 h. Each treatment also
caused apoptosis, as measured by increased caspase3/7 activity and a
lower viable cell number. An osmolality control had no effect on these
end-points.
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(% of control)
Apoptosis Markers
(% of control)
Total
protein/cell
No.
ANP
mRNA
α-sk
actin
mRNA
Caspase
3/7
Activity
Viable
cell
number
rhCTGF
(500 ng/mL)
183±22* 145±16* 129±10* 179±12* 79±8*
Glucose
(30 mM)
148±24* 340±43* 201±27* 228±5.0* 79±2*
Palmitate
(50 μM)
165±29* 161±23* 155±18* 192±19* 68±5*
Palmitate
(100 μM)
397±7.0* 143±24 189±39* 262±49* 53±5*
Glucose
(30 mM) +
CTGF SiRNA
114±16
+ ND ND 156.3±17
+ 88±8
+
Palmitate
(50 μM) +
CTGF SiRNA
107±1.8
+ ND ND 123.5±35
+ 98±7
+
Mean±SD; *P<0.05 compared with respective untreated control,
+P<
0.05 compared with respective treatment+scramble SiRNA negative
control by ANOVA; ND–not done. Further studies showed that CTGF
mRNA was induced at 16 h by high glucose (30 mM) and palmitate
(50 μM) to 162% and 300% of control, respectively (P<0.05). SiRNA
(5 nM) against CTGF lowered steady state CTGF mRNA levels to
81% of control; it completely blocked the high glucose and palmitate
induction of hypertrophy, and partially inhibited the up-regulated
caspase 3/7 activity (Table). In contrast, a scrambled RNA control
sequence had no effect on these parameters. In addition, these CTGF
effects were through the trkA receptor with tyrosine kinase activity,
which has previously been implicated in CTGF signalling: trkA was
phosphorylated by CTGF in these cells by Western analysis, and a
specific trkA blocker (100 nM k252a, Merck) abrogated CTGF-
induced trkA phosporylation and CTGF effects on hypertrophy and
apoptosis. Pre-incubation of cells with the cardioprotective incretin,
glucagon-like peptide-1 (GLP-1) prevented the CCN2, high glucose
and palmitate induced increase in caspase and the reduction in viable
cell number. Collectively, this data implicates autocrine CTGF as a
mediator in adverse effects of high glucose and fatty acids on
cardiomyocytes, through trkA mediated mechanisms. Supported by
NHMRC Australia.
BALANCING CCN-2 (CTGF) AND BMP(S)
IN COMPLICATIONS OF DIABETES MELLITUS
Roel Goldschmeding
1, Noelynn Oliver
2, and Tri Q. Nguyen
1
Department of Pathology, University Medical Center Utrecht, The
Netherlands, FibroGen Inc., South San Francisco, CA, USA
Recently, CCN-2 (connective tissue growth factor; CTGF) and bone
morphogenetic proteins (BMPs) have emerged as key players in
diabetic nephropathy. In experimental diabetic nephropathy, the
expression of BMP-7 is decreased and BMP antagonists are increased,
while BMP-7 treatment improves outcome.
On the other hand, CCN-2 is strongly upregulated in experimental
and human diabetic nephropathy. In patients with diabetic nephrop-
athy, both urinary CCN-2 excretion and plasma CCN-2 are increased
and correlate with clinical markers of renal disease. The association of
elevated CCN-2 levels with diabetic nephropathy was found to be at
least as strong as that of the established risk factors hypertension and
hyperglycemia. Baseline plasma CCN-2 was an independent predictor
of end-stage renal disease and mortality in patients with diabetic
nephropathy. Furthermore, in diabetic patients with nephrotic range
albuminuria, plasma CCN-2 was the only parameter predicting end-
stage renal disease. These observations suggest that CCN-2 in urine
and plasma might find clinical application as a biomarker.
The involvement of CCN-2 in the pathogenesis of experimental
diabetic nephropathy and its complications has been demonstrated by
modulation of CCN-2 levels by genetic deletion and overexpression,
and by treatment with CCN-2 antisense oligodeoxynucleotides or
CCN-2 neutralizing antibody. These modulations significantly affect-
ed the magnitude of structural and functional changes, including
matrix metalloproteinase activity, extracellular matrix accumulation,
glomerular basement membrane thickening, albuminuria, serum
creatinine, as well as cardiovascular function. Interestingly, CCN-2
was found to inhibit the renal signaling activity and target gene
expression of BMP-7, both in diabetic mice and in cultured renal cells.
Also in human diabetic nephropathy BMP signalling activity was
diminished, together with reduction of podocyte markers. These
changes were associated with overexpression of CCN-2 but not
SOSTDC1.
In conclusion, CCN-2/CTGF emerges as a critical determinant of
diabetic nephropathy and cardiovascular disease. At least in the
kidney, it’s role appears to involve inhibition of BMP-signaling
activity. Better understanding of the interplay between CCN-2 and
BMPs might guide development of novel biomarkers and therapeutic
strategies, but also investigation of the impact of CCN-2 on other
pathways will be important.
CCN2/CTGF IS TRANSACTIVATED THROUGH ITS
ENHANCER ELEMENT BY SOX9 IN FIBROBLASTS:
POSSIBLE ROLES IN FIBROSIS
Takako Hattori
1, Yurika Uchida
1, Hiroshi Ikegawa
1, Nao Tomita
1,
Sonali Sonnylal
2, Benoit de Crombrugghe
2, Masaharu Takigawa
1
1Department of Biochemistry & Molecular Dentistry,
Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences, Okayama, Japan,
2Department
of Molecular Genetics, The University of Texas,
MD Anderson Cancer Center, Houston, TX, U.S.A
Accumulation of extracellular matrix proteins is one of the character-
istic pathological changes in sclerotic fibroblasts. CCN2/CTGF which
is expressed predominantly in prehypertrophic chondrocytes in the
physiological state, but also in many types of fibroblasts under
pathological conditions, is involved in the pathogenesis of sclerosis
through strong induction of synthesis and accumulation of extracel-
lular matrix components. Sox9, a transcriptional regulator for
cartilage-specific extracellular matrix components, is essential for the
chondrocytic cell fate and also strongly expressed in prehypertrophic
chondrocytes. Here we propose that 1) Sox9 may regulate ccn2/ctgf
expression in chondrocytes, and 2) that there may be a relationship
between overexpression of CCN2/CTGF and enhanced Sox9 expres-
sion in fibroblasts and the pathogenesis of sclerosis.
In this report, we identified Sox9-enhancer regions in the ccn2/ctgf
promoter by deletion analysis of ccn2/ctgf promoter-reporter con-
structs; mutations within the enhancer region abrogated promoter
activitation by Sox9. Sox9 bound to the enhancer region of ccn2/ctgf
in vitro as shown by gel shift assays. Chromatin immunoprecipitation
analysis using Sox9 antibodies effectively precipitated the ccn2/ctgf
enhancer, confirming Sox9-binding to the ccn2/ctgf enhancer in vivo.
Conversely, embryonic fibroblasts from skin-specifically ccn2/ctgf-
overexpressing mice showed enhanced expression of Sox9 and
aggrecan mRNA in comparison to wildtype fibroblasts, and adult
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proteins. Similarly, cartilage-specifically ccn2/ctgf-overexpressing
mice showed enhanced expression of Sox9 and aggrecan mRNA in
cartilage. These findings indicate a stimulatory feed back loop in
which overexpression of CCN2/CTGF stimulates expression of Sox9,
and the induced Sox9 further promotes CCN2/CTGF expression,
resulting in accelerated CCN2/CTGF production and aggrecan
accumulation. This may be the cue to the pathogenesis of experimen-
tal fibrosis.
IN VIVO EFFECTS OF CCN5 OVEREXPRESSION
IN FIBROIDS
Joshua Russo, John Castellot
Department of Anatomy and Cell Biology
Tufts University School of Medicine, Boston MA, USA
Uterine leiomyoma (fibroids) are smooth muscle tumors that form in
the myometrial layer of the uterus. They are the most common of all
tumors in women and in the United States result in over 200,000 total
abdominal hysterectomies in symptomatic patients every year.
Clinically symptomatic fibroids are present in 15–20% of the general
female population, and the prevalence rises to >60% in women of
African decent. Currently, the only treatment proven to prevent
recurrence of the disease is the relatively invasive procedure of total
abdominal hysterectomy. The development of less drastic therapeutic
alternatives requires a detailed understanding of the cellular and
molecular mechanisms regulating the proliferation of both fibroid and
normal SMC. Earlier work in our laboratory has shown that primary
cultures of neoplastic SMC cells isolated from fibroids display no
endogenous production of CCN5 protein, while SMC derived from
the myometrium of the same patients display normal levels of CCN5.
In addition, forced expression of CCN5 utilizing an adenoviral system
inhibits the proliferation and motility of cultured fibroid cells. When
CCN5 overexpression is attempted in an in vivo model similar results
are found. Adenoviral overexpression of CCN5 in the rat leiomyoma
cell line ELT-3 inhibits the in vivo formation of tumors by these cells
and decreases tumor mass by 72%. Also of great interest to the field of
fibroid research is the recent success our lab has had in the
development of an in vivo leiomyoma model that utilizes human
fibroid cells. Currently the field lacks a human-based in vivo system to
study the effects of potential therapeutics such as CCN5. Using freshly
isolated human fibroid tissue organoids suspended in a matrigel/
collagen I mixture, a subcutaneous injection of the organoid
suspension, followed by whole animal hormone supplementation,
results in the growth of the human smooth muscle cells out of the
injection site where they acquire a blood supply through angiogenesis.
Experiments to demonstrate the inhibitory effects of CCN5 over-
expression on human uterine smooth muscle cells within this new in
vivo system are underway. These data bring us one step closer to the
realization of CCN5 as a potential therapeutic for multiple smooth
muscle pathologies, including uterine fibroids.
Supported by NIH Grant HD046251
MICROVASCULAR PERICYTES EXPRESS CCN2 IN TISSUE
FIBROSIS
Shiwen X., Rajkumar V., Stratton R., Renzoni E., Denton C.,
Abraham D, Leask A
Department of Medicine, University College London, Rowland Hill
St., London NW3 2PF United Kingdom; Division of Oral Biology,
University of Western Ontario, London ON, Canada, N6A 5C1
The cell and molecular mechanisms that link microvascular damage to
the fibrogenic pathology in systemic sclerosis (SSc) are not fully
understood. However, the endothelium-derived production of endothe-
lin-1 (ET-1) and the fibroblast-derived production of CCN2 are likely to
play key roles in this process. Dermal fibroblasts (DF; n=6) were
obtained from control and SSc tissue. Pericytes were isolated from
human placenta. Gene expression profiles of fibroblasts and pericytes
was assessed by gene chip using the Affymetrix U133A gene chips and
analyzed by D-Chip software in the presence or absence of ET-1
(100 nM). The effect of ET-1 the phenotype of normal, SSc fibroblasts
and pericytes was also assessed by functional assays. Early cultured
pericytes (passage < 4) expressed a-SMA and CCN2, but little or no
expression of the fibroblast marker AS02 or collagen type I (p<0.05).In
late passage pericytes (passage >5), AS02 and collagen type I
production were significantly increased (p<0.05). ET-1 significantly
stimulated pericytes and normal fibroblasts to produce CCN2 and
collagen (p<0.05). These data strongly suggest that pericytes can
acquire a fibrogenic phenotype suggesting that this cell type may be
linked to the fibrosis in SSc. Thus pericytes represent an additional cell
type that must be taken into account when considering pathogenic
mechanisms and therapeutic targets in SSc.
EPITHELIAL AND CONNECTIVE TISSUE CELL CTGF/
CCN2 EXPRESSION IN GINGIVAL FIBROSIS: ROLE
OF EPITHELIAL-MESENCHYMAL TRANSITION
Alpdogan Kantarci, Siddika S. Sume, Samuel A. Black, Alan Lee,
Cristina Xydas, Hatice Hasturk, Philip C. Trackman
Department of Periodontology and Oral Biology, Boston University,
Goldman School of Dental Medicine, Boston, MA, USA
Drug-induced gingival fibrosis is a common side effect of certain
medications, and non-drug induced forms occur either as rare
inherited or idiopathic gingival fibromatosis (GF). In the present
study, we have investigated both the epithelial and connective
tissue expression of CTGF/CCN2 in gingival fibrosis. Findings
prompted us to investigate epithelial-mesenchymal transition
(EMT), as a possible mechanism underlying these gingival
pathologies. Gingival overgrowth samples were from subjects
receiving phenytoin (PHE), nifedipine (NIF), or Cyclosporin A
(CsA), or diagnosed with GF. Control tissues were from healthy
donors. Connective tissue growth factor (CTGF/CCN2) expression
in connective tissue fibroblasts was positively related with the
degree of fibrosis. Cellular and extracellular CTGF/CCN2 content
in PHE and GF tissues was significantly (p<0.05) higher (4-7-fold
and 5-6-fold, respectively) compared to the other drug-induced
gingival overgrowth tissues and the controls. Higher CTGF/CCN2
staining was accompanied by an increased abundance of fibroblasts
and connective tissue fibers. CTGF/CCN2 was also highly expressed
in the epithelium of fibrotic gingival tissues. This finding was
confirmed by in situ hybridization. Real time PCR analyses of RNA
extracted from control and drug-induced gingival overgrowth tissues
for CTGF/CCN2 were fully consistent with these findings. Normal
primary gingival epithelial cell cultures were next analyzed for the
basal and TGF-β1—or lysophosphatidic-acid stimulated CTGF/
CCN2 expression at the protein and RNA levels. Cultured epithelial
cells express CTGF/CCN2, and TGF-β1 and lysophosphatidic acid
each further stimulates CTGF/CCN2 expression, but with different
kinetics. As an indication of EMT, the levels of E-cadherin, a
specific marker of epithelial cells, were significantly lower in
gingival fibrosis compared to control tissues while there was no
detectable expression in fibroblasts. Meanwhile, epithelial Fsp-1,
which is a marker of mesenchymal cells, showed a significant
increase in oral epithelium of gingival fibrosis samples compared to
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CCN2 in promoting development of fibrotic lesions in human
gingiva while interactions between epithelium and stroma in the
form of EMT seem likely to contribute to gingival fibrosis.
Supported by USPHS Grants DE11004 and RR00533.
FIBROSIS IN DUCHENNE MUSCULAR DYSTROPHY; ROLE
OF CCN2 AND ITS POTENTIAL INHIBITION BY DECORIN
Daniel Cabrera
1, Cecilia Vial
1, Claudio Cabello-Verrugio
1,
Enrique Brandan
1
1Laboratory of Cell Differentiation and Pathology, Department of Cell
and Molecular Biology, Faculty of Biological Science, CRCP, CARE,
Catholic University of Chile. Santiago, Chile
One of the features of Duchenne Muscular Dystrophy (DMD) is the
progressive accumulation of extracellular matrix (ECM) in a process
called fibrosis. In the murine model of DMD, the mdx mouse, fibrosis is
quite evident in the diaphragm but less prominent in leg muscles such as
tibialis anterior. Connective tissue growth factor (CCN2/CTGF) a pro-
fibrotic growth factor has been implicated as one of the key mediators of
fibrosis in many tissues. The exact role of CTGF in skeletal muscle
fibrosis, as well as, its effect on myoblasts and myotubes is unknown.
Mdx mice under exercise protocols (1 month, twice per week) shown an
importantaugmentinfibrosis,characterizedbyanincreaseinfibronectin,
collagen type III and periostin, together with CTGF. Myoblasts and
myotubes are able to synthesize CTGF in response to transforming
growth factor type-b (TGF-b) and lysophosphatidic acid (LPA). In
myoblasts, CTGF increase the amount of ECM molecules and down-
regulates desmin and MyoD, inducing a loss of the commitment of this
cell to the muscle cell lineage. Myoblasts null for the proteoglycan
decorin, show increased basal level of ECM molecules and an enhanced
response to CTGF compared to wild type myoblasts, suggesting an
inhibitory effect of decorin on CTGF activity. In fact, the addition of
soluble decorin caused an inhibition of CTGF activity in wild type
myoblasts and fibroblasts. Furthermore, co-immunoprecipitation assays
of purified CTGF and decorin indicate that both molecules directly
interact. Interestingly, decorin is endocytosed, in myoblasts but not in
myotubes through LDL receptor-related protein (LRP), a known receptor
of CTGF. In summary, these results suggest that CTGF is implicated in
skeletal muscle fibrosis, which myoblasts contribute to this fibrotic
process.CTGFdedifferentiatemyoblast,arepaircellsourceinDMDand,
decorin inhibits CTGF fibrotic activity by direct interaction with the
growth factor.
(Support from CRCP, CARE, MDA and MIFAB)
TISSUE-SPECIFIC REGULATION OF CCN2/CTGF
IN GINGIVAL FIBROBLASTS AND ITS RELATIONSHIP
TO GINGIVAL FIBROSIS
Samuel A. Black, Jr., and Philip C. Trackman
Boston University Goldman School of Dental Medicine, Department
of Periodontology and Oral Biology Boston, MA, USA 02118
Connective tissue growth factor (CCN2/CTGF) is expressed at high
levels in some forms of gingival overgrowth. Lesions in severe cases
coverteethand interferewith normalmasticatory function andtreatments
include repeated surgical excisions. Regulation of CCN2/CTGF expres-
sion in human gingival fibroblasts is unique and is related to the tissue-
specificity of this pathology. TGFβ1-stimulated expression of CCN2/
CTGF in gingival fibroblasts is resistant to inhibition by PGE2,w h e r e a s
human lung and renal fibroblastic cells are highly sensitive. Resistance
in gingival fibroblasts is conferred by two mechanisms: (1) activation of
the EP3 prostanoid receptor that results in stimulation of Jun-N-terminal
kinase (JNK1); and (2) a weak cAMP response and weak inhibition of
JNK1 resulting from activation of the EP2 prostanoid receptor. Data
show that JNK1 is the major MAP kinase required for the TGFβ1-
induced expression of CTGF in gingival fibroblasts determined in
studies employing pharmacologic inhibitors, and recombinant domi-
nant-negative JNK1 adenovirus. Stimulation of adenylate cyclase with
forskolin more significantly reduces JNK activation in response to
TGFβ1 in gingival-compared to lung fibroblasts. Specific activation of
the EP3 receptor with sulprostone enhances JNK1 activation in gingival
fibroblasts. Thus, EP3 activation by PGE2 is a mechanism by which
gingival cells overcome the inhibition of CTGF expression caused by
the stimulation of cAMP accumulation in response to stimulation of the
EP2 prostanoid receptor or forskolin. TGFβ1-induced expression of
CCN2/CTGF in gingival fibroblasts is independent of the activation of
the small GTPase, RhoA. While RhoA is not involved in mediating the
TGFβ1-stimulated expression of CCN2/CTGF in gingival fibroblasts,
Rho-family GTPases Rac1 and Cdc42 are. This was demonstrated by
overexpression of recombinant dominant-negative adenoviral forms of
RhoA, Rac1 and Cdc42 in gingival fibroblasts, and effects of TGF-β1
regulation of CCN2/CTGF determined. Results were independently
confirmed with pull-down assays for activated RhoA, in which LPA
stimulation of gingival fibroblasts resulted in detecting activated RhoA,
whereas TGF-β1 did not activate RhoA. These findings have permitted us
to propose a potential treatment strategy to block CCN2/CTGF expression
in gingiva that independently targets two complementary pathways. The
combination of the HMG-CoA reductase inhibitor lovastatin, which
blocks the activation of small GTPases, and the adenylate cyclase
activator, forskolin (a JNK inhibitor in gingival cells), together reduce
TGF-β1 stimulated CCN2/CTGF protein levels to unstimulated levels.
Additional studies in progress are furthering our understanding of unique
aspects of CCN2/CTGF regulation that may similarly be potentially
addressed by pharmacologic approaches. Supported by NIH grants R01
DE11004, M01 RR00533, and K08 DE016609.
CCN3 (NOV) IS A NEGATIVE REGULATOR OF CCN2
(CTGF) AND A NOVEL ENDOGENOUS INHIBITOR
OF FIBROSIS IN EXPERIMENTAL NEPHROPATHY
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Fibrosis is a major cause of end stage renal disease (ESRD), and
although factors responsible for its initiation are being elucidated, a lack
of understanding of the downstream regulatory pathways has prevented
development of specific anti-fibrotic therapies. CCN2 (CTGF) has
emerged as a critical molecule acting downstream of TGF-b to drive
fibrosis, making it a new therapeutic target. However, suppression of
CCN2 has been difficult. We examined the possibility that CCN3
(NOV), another CCN family member with different reported biological
activities, might act as an endogenous negative regulator of CCN2 with
the capacity to limit the fibrotic response, including the overproduction
of extracellular matrix (ECM). We demonstrate for the first time, using
an in vitro model of renal fibrosis, that both exogenous treatment and
transfection with the over-expression of the CCN3 gene, in mesangial
cells markedly down-regulates CCN2 activity and blocks ECM over-
accumulation stimulated by TGF-b. Conversely, TGF-b treatment
reduces endogenous CCN3 expression and increases CCN2 activity
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effect. Preliminary animal studies support these in vitro findings. CCN3
then, as a negative regulatory molecule of CCN2 and the effects of
TGF-b, may act naturally to limit fibrosis in vivo, and therefore provide
opportunities for novel endogenous-based therapy.
TARGETED CCN2 GENE THERAPY IN EXPERIMENTAL
LIVER FIBROSIS
David R Brigstock
1,2,3
1Center for Cell and Developmental Biology, The Research Institute at
Nationwide Children’s Hospital, Columbus OH USA
2Department of Surgery and
3 Department of Molecular and Cellular
Biochemistry
The Ohio State University, Columbus OH USA
Hepatic stellate cells (HSC) are a relatively minor and normally
quiescent cell population in the liver that reside in the space of Disse
and which, following injury, become “activated” into α-smooth
muscle actin (αSMA)-expressing myofibroblastic cells. Upon activa-
tion, HSC are responsible for deposition of excess scar tissue through
their production of collagen types I and III, proteoglycans, fibronectin,
laminin and activation of tissue inhibitors of matrix metalloproteases
which prevents fibrolysis by inhibiting matrix metalloprotease activity.
Recent data have firmly established that CCN2 is an important
player in HSC biology. CCN2 is produced by HSC either as a function
of activation or in response to stimulation of the cells by pro-fibrotic
molecules or growth factors. CCN2 mRNA and protein are increas-
ingly expressed during progressive activation of cultured primary rat
HSC, or in response of the cells to stimulation by TGF-β, VEGF, lipid
peroxidation products, acetaldehyde or PDGF-BB. The CCN2
receptor, integrin αvβ3, is strongly upregulated during HSC activation
allowing CCN2 to drive adhesion, migration, proliferation, and
fibrogenesis in activated cells but not their quiescent counterparts.
CCN2 is also a survival factor for activated HSC.
These data show that CCN2 drives both fibrogenic and anti-
apoptotic pathways in HSC and reinforce the notion that CCN2 is a
realistic therapeutic target in liver fibrosis. To address this question
directly, we developed a strategy to specifically target CCN2
production in activated HSC in vivo, as tested in mouse models of
hepatic fibrosis. Modified liposomes containing CCN2 siRNA were
coated with a synthetic peptide that was designed to home specifically
to activated HSC in vivo. Balb/c mice received daily injections of
CCl4 or oil control for 3 weeks (preventative model) or 5 weeks
(curative model) and, for the last 2 weeks of each regimen, some mice
also received daily treatments of CTGF siRNA in the targeted
liposomes. Hepatic mRNA or protein levels of key fibrotic markers
(CCN2, TGF-β, αSMA, collagen 1) were assessed and showed that in
both preventative and curative models, the targeted liposomes were
completely effective as an anti-fibrotic therapy, and were significantly
more efficacious than their non-targeted counterparts.
These data (i) show that attenuation of CCN2 production in
activated HSC in fibrosing liver is an effective anti-fibrotic strategy
and (ii) demonstrate the utility of a targeted HSC approach as a means
of delivering and testing therapeutic agents.
CELL TYPE-SPECIFIC REGULATION OF CONNECTIVE
TISSUE GROWTH FACTOR BY HYPOXIA
Jana Samarin, Julia Wessel, Emily Neubauer, Sven Kroening,
Margarete Goppelt-Struebe
Department of Nephrology and Hypertension, University of Erlangen-
Nuremberg
Connective tissue growth factor (CTGF) is a matricelluar protein which
interacts with VEGF and thus modulates angiogenesis. Hypoxia, a major
stimulus of angiogenesis in tumor tissue, has been connected to the
induction of CTGF. However, upregulation of CTGF was not consistently
observed. Therefore, the aim of the present study was to investigate the
molecular mechanisms of hypoxia-induced regulation of CTGF.
Expression of CTGF was investigated in various cell lines,
particularly in established microvascular endothelial cell lines (glEND.2,
HMEC) and human proximal tubular epithelial cell lines, (HK-2,
HKC8) as well as human primary tubular cells. Cells were exposed to
hypoxia or stimulated with dimethyloxalylglycine (DMOG), which
leads to the stabilization of the hypoxia-inducible factor HIF-1a.
Upregulation of CTGF was observed in human and mouse endothelial
cells, whereas no change or down-regulation was detectable in tubular
epithelial cells. DMOG-mediated stabilization of HIF-1a was linked to
CTGF expression in endothelial cells, because siRNA against HIF-1a
reduced CTGF expression. However, HIF-1a was stabilized in all cell
types exposed to DMOG suggesting the existence of cell-type specific
co-regulators.
Several signaling pathways, which have previously been shown to
be relevant for CTGF induction, were not involved in hypoxia-
induced CTGF expression (MAPkinases p42/44 and p38, or RhoA-
associated kinase). Inhibition of PI3-kinase-AKT signaling by
LY294002, however, strongly induced basal and DMOG-stimulated
CTGF expression in endothelial cells, whereas in epithelial cells,
CTGF was slightly downregulated.
The kinase AKT negatively regulates transcription factors of the
FoxO family, which are active in their dephosphorylated form. FoxO
1/3 siRNA significantly reduced induction of CTGF by LY294002 in
endothelial cells, establishing FoxO proteins as downstream mediators
of AKT, relevant for the induction of CTGF. Furthermore, hypoxia–
and DMOG-induced CTGF expression was also reduced by FoxO 1/3
siRNA, suggesting a connection between HIF-1a signaling and
regulation of FoxO 1/3 activity.
FoxO transcription factors have been previously described as
context-dependent regulators of cell growth and differentiation. In this
study, we were able to link these transcription factors to the cell type-
specific regulation of CTGF and demonstrate their relevance for the
differential regulation of CTGF by hypoxia, the functional implica-
tions of which need further consideration.
ELASTIN RECEPTOR SUBUNITS FACILITATE ELASTIC
FIBER ASSEMBLY AND MODULATE CELLULAR
PROLIFERATION
Aleksander Hinek
The Hospital for Sick Children, University of Toronto, Ontario,
Canada
We have discovered that the elastin-binding protein, which is identical
to the spliced variant of ß-galactosidase, forms a cell-surface-targeted
complex with two proteins considered as “classic lysosomal enzymes,”
protective protein/cathepsin A (PPCA) and neuraminidase-1 (Neu1).
This recyclable complex can also bind intracellular tropoelastin and
serve as a molecular chaperone for this precursor of elastin.
We have also establish that transgenic mice deficient either in Neu1 or
PPCA do not assembly normal elastic fibers. This observation, and
additional results from extensive in vitro studies lead to the conclusion
that the cell-surface-residing that PPCA proteolytically activates Neu1,
which in turn desialylates neighboring microfibrillar glycoproteins and
facilitate the deposition of insoluble elastin. Recently, we also introduced
a novel mechanism in which Neu1 may limits proliferation of human
arterial smooth muscle cells (SMC) and skin fibroblasts by desialylating
their cell membrane-residing sialoglycoproteins that directly propagate
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neuraminidase inhibitor or with anti-Neu1 antibody induced significant
up regulation in their proliferation in response to the growth factors-rich
fetal serum. Conversely, treatment with Clostridium perfringens neur-
aminidase (which is highly homologous to Neu1) decreased SMC’s
proliferation. We further found that pretreatment of SMCs and skin
fibroblasts with neuraminidase abolished their mitogenic response to
recombinant PDGF-BB and IGF-II, and that fibroblasts derived from
Sialidosis patients (which are exclusively deficient in Neu1) were more
responsive to PDGF-BB and IGF-II than normal fibroblasts. Furthermore,
we provided evidence that neuraminidase caused desialylation of the
PDGF–and IGF-1 receptors and diminished intracellular signals induced
by their mitogenic ligands, PDGF-BB and IGF-II.
The most recent data indicate that Neu1 also desialylates the cell
surface insulin receptor (IR) on skeletal cells myoblasts (L6WT).
However, in contrast to an inhibitory effect on cellular proliferation
observed after desialylation of IGF-1R or PDGFR, the removal of sialic
acids from IR of L6WT cells leads to a more potent metabolic and
proliferative response to physiological dose (10 nM) of insulin.
We also found that PPCA-deficient mice, which in addition to
Galactosialidosis phenotype are characterized with arterial hypertension,
demonstrate significantly heightened levels of Endothelin-1 (ET-1).
Importantly, we also provided evidence that cell surface-residing PPCA
plays a non redundant role in the regulation of blood pressure through
proteolytic inactivation of a potent vasoconstrictor and mitogen, ET-1.
ABNORMAL EXTRACELLULAR MATRICES IN RARE
AND COMMON DISORDERS
William G. Cole
Research Institute, Hospital for Sick Children, Toronto, Ontario,
Canada
Many of the genes required for the normal structure and function of
the connective tissues have been identified from the study of rare
genetic disorders. Many of the genes encode macromolecules of the
extracellular matrices but others are involved in cell signalling, cell
adhesion and cell-matrix interactions. Examples include the fibrillar
and other collagens, thrombospondins such as cartilage oligomeric
matrix protein, and matrilins such as matrilin 3. The combination of
protein studies using cell cultures from affected patients as well as
tissues and cultures from animal models have provided valuable
insights into the structural and functional consequences of mutations.
In patients with lethal or very severe phenotypes the mutant gene effect
sizes are overwhelming so that recurrent mutations can be expected to
be yield similarly severe phenotypes. For example, glycine substitu-
tions within the triple helical domain of the type I collagen chains in
lethal forms of osteogenesis imperfecta severely impair the assembly,
modifications and secretion of type I collagen molecules. The
extracellular matrices are very abnormal. The type I collagen producing
cells undergo an endoplasmic reticulum stress survival response,
impaired differentiation and apoptosis. In contrast, genetically deter-
mined connective tissue disorders that become clinically evident in late
childhood and in adulthood are usually milder and show more
phenotypic variability than those that manifest early. An example, is
the common form of osteogenesis imperfecta which is associated with
COL1A1 haploinsufficiency and highly variable skeletal fragility. In
such individuals, the mutant COL1A1 gene effect size is likely to be
less than for COL1A1 mutations that produce lethal phenotypes. It is
also likely that the variable skeletal fragility is due to the differing
genetic backgrounds and environmental influences amongst different
family members that bear the same COL1A1 mutation. Currently, little
is known about the genes and environmental factors that determine the
susceptibility or resistance to COL1A1 haploinsufficiency. Studies of
various bone health parameters, such as peak bone mass, in man and in
inbred mice have shown that most traits are determined by many gene
variants that each exert very small effects on the phenotype of interest.
These various findings suggest that the normal development, mainte-
nance and repair of tissues such as bone and cartilage are controlled by
sets of ‘bone health’ and ‘cartilage health’ genes that act in networks.
The relative contribution of various genes and their protein products
may vary throughout life. The health of the tissue is likely to be largely
determined by the genetic variants that an individual bears. Novel
strategies are now available to define the gene and protein networks and
to identify the patterns that are associated with the onset of connective
tissue disorders at various ages.
CELL AND GENE THERAPY PRESERVES MATRIX
HOMEOSTASIS: A NOVEL PARACRINE MECHANISM
Ren-Ke Li
University of Toronto, Toronto General Research Institute, MaRS
Center Toronto Medical Discovery Tower Toronto, Ontario
Current attempts to regenerate the damaged myocardium after a
myocardial infarction have focused on therapies directed at increasing
regional perfusion and salvaging viable cardiomyocytes. Accumulat-
ing evidence suggests that implanting healthy muscle cells into the
damaged myocardium can prevent infarct thinning and chamber
dilatation. Cell transplantation has been proposed to encourage the
recruitment of stem cells from the bone marrow or the heart to
repopulate the infarcted region. Within the myocardial scar tissue,
these neo-myogenic cells can prevent ventricular dilatation and delay
the onset of cardiac dysfunction. Early clinical trials suggest
encouraging results for cell therapy.
Although the favourable effects of cell therapy on post-infarction
myocardial regeneration have been observed, the underlying mechanisms
have not yet been elucidated. For example, while stimulating neo-vessel
formation and muscle cell engraftment within the scar may contribute to
enhanced regional and global function, the number of cells surviving
implantation is too small to alone account for these functional benefits.
An alternative explanation may involve the effect of the engrafted
cells on remodeling of the extracellular matrix, which is initiated
following a myocardial infarction by the imbalance between matrix
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs).
Matrix remodeling is recognized as a central process underlying the
maladaptive reorganization of cardiac size, shape, and function that
determines the progression of heart failure. Disruption of the matrix
network may contribute to cardiomyocyte apoptosis, leading to
chamber dilatation. We have demonstrated that cell transplantation
can prevent scar thinning and cardiac dilatation after an infarction by
altering the response of the matrix or restoring its structure. We found
that smooth muscle cells implanted into animal hearts survived and
altered matrix remodeling both within and remote from the region of
implantation. We also observed decreased matrix metalloproteinase
(MMP-2 and -9) activities in transplanted compared to control hearts.
The results were maintenance of the matrix structure, and prevention
of ventricular dilatation.
To enhance cell therapy-induced matrix preservation by regulating
MMP inhibition in the infarcted and remote myocardium, we implanted
the infarcted heart with cells genetically modified to over-express TIMP-
3. These studies established the proof of concept for cell-based gene
therapy as an effective, clinically-relevant approach to matrix modula-
tion. We also identified an intricate dose–and time-dependant effect of
TIMP-3 over-expression in the modulation of cardiac remodeling. Our
results highlight the efficacy of cell-b a s e dg e n ed e l i v e r ys y s t e m sa n dt h e
synergistic benefit of gene and cell therapies used to target matrix
remodeling after a myocardial infarction.
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dilatation through an alteration of matrix metabolism, which is a possible
mechanism by which cell transplantation improves heart function.
MT1-MMP AND CONTRACTILITY PROMOTE INVASIVE
BEHAVIOUR BY OVARIAN CANCER CELLS
Katherine Sodek
Department of Cell and Systems Biology, University of Toronto
Cell- matrix interactions modulate cell fate, polarity, motility,
survival and invasion in both physiological and pathological
processes. Ovarian cancer, the most lethal gynaecological cancer, is
typically detected at a late/advanced stage subsequent to metastasis
within the peritoneal cavity. Since cell motility and degradation are
important contributors to tissue invasion, it is critical to use in vitro
assay systems that best reflect the circumstances in vivo. Evaluation of
Matrigel and collagen I matrices as representatives of basement
membrane and stromal matrix barriers respectively, revealed the
inadequacy of Matrigel, which cells penetrated in absence of matrix
metalloprotease (MMP)-mediated matrix degradation. MT1-MMP
(MMP-14), a transmembrane MMP with potent pericellular proteo-
lytic activity, was determined to be a critical mediator of collagen I
matrix degradation and invasion by ovarian cancer cells, and its
ectopic expression conferred an invasive ability to previously non-
invasive cell lines. Although cells that expressed MT1-MMP were
generally more motile, MT1-MMP did not promote cell motility.
Proteomic profiling of the cell lines was therefore performed to reveal
factors contributing to the divergent motile capacities. Several
proteases, integrin subunits, and proteins that mediate actin cytoskel-
etal dynamics were upregulated in the motile cell lines, supporting the
importance of cell-matrix interactions in stimulating this behaviour.
Within peritoneal ascites fluid, ovarian cancer cells exist both
individually and as multicellular spheroid aggregates. Spheroid aggre-
gates contain abundant matrix and the constituent cells have enhanced
resistance to radiation and many chemotherapeutics. A striking correla-
tion was evident between the ability of the cells to form compact
spheroids and their capacity to invade/penetrate in a 3D culture system.
These data suggest that behaviours possessed by the invasive cell lines
promote their spheroid formation such that an aggressive cancer cell sub-
population may acquire preferential resistance to chemotherapeutics.
Intriguingly, in this 3D model, although MMP activity was required for
invasion, additional factors related to cell motility appeared to limit
spheroid cell dissemination. Contractile behaviour and a mesenchymal
phenotype were characteristics common to the invasive, compact
spheroid forming cell lines. Furthermore, preliminary data indicate
CCN proteins, particularly CTGF and NOV, to be upregulated in the
3D-invasive, compact spheroid-forming subset of cell lines. The role of
MT1-MMP and contractile behaviour as potential contributors to ovarian
cancer metastasis will be discussed, as well as issues relating to the use
of collagen I and Matrigel as invasion matrices in 2D transwell and 3D
invasion systems.
CCN3 PROMOTES MELANOMA PROGRESSION
BY REGULATING INTEGRIN EXPRESSION, ADHESION
AND CHEMORESISTANCE
Viviana Vallacchi
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Overexpression of CCN3 was detected in metastatic melanoma cells as
compared to cells of the primary tumor from the same patient. Analysis
of CCN3 in short-term cultures from 50 melanoma lesions revealed a
heterogeneous expression of the 46-kDa full-length protein and the 32-
kDa truncated form. In fact, some melanomas were negative for CCN3
expression, while others expressed both isoforms at the cellular level and
secreted in the culture medium. Other melanomas displayed only the full-
length or only the short isoform with or without protein secretion. The
different protein expression patterns were not associated with gene
alterations or polymorphisms. Cell fractions and immunofluorescence
analysis demonstrated that the 46-kDa protein has a prevalent cytoplas-
mic localization, while the 32-kDa form has a nuclear localization and
lacked the N-terminal domain.
Similarly to metastatic cells expressing high levels of CCN3, cells
transfected to overexpress CCN3, despite a reduction in cell proliferation,
showed increased adhesion to ECM proteins, particularly laminin and
vitronectin, while inhibition of CCN3 expression by siRNA decreased
adhesion. CCN3 overexpression increased expression of laminin and
vitronectin integrin receptors α7β1a n dαvβ5b yi n c r e a s i n gt h e i rm R N A
production. Moreover, CCN3 secreted by melanoma cells acted as an
adhesion matrix protein for melanoma cells themselves.
Immunohistochemistry performed on melanoma specimens from
which the cell lines were derived confirmed that the different levels of
expression occurring in vivo are maintained in cultured cells. Analysis of
CCN3 protein expression with respect to melanoma progression detected
the protein in all visceral metastases tested and in most nodal metastases
from relapsing patients, but only in a few nodal metastases from non-
relapsing patients and cutaneous metastases. Consistently, xenotrasplan-
tation in immunodeficient mice showed a higher metastatic potential of
melanoma cells overexpressing CCN3. CCN3-transfected cells showed a
higher resistance to apoptosis-induced by treatment with cytotoxic drugs.
Taken together, these data indicate a role for CCN3 in melanoma cell
interaction with the ECM by regulating integrin expression, resulting in
altered cell adhesion and increased chemoresistance, leading melanoma
progression to aggressive disease.
CCN3 RESTORES GROWTH REGULATION IN CHRONIC
MYELOID LEUKAEMIA
L. McCallum
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Chronic Myeloid Leukaemia (CML) is characterized by expression of
the constitutively active Bcr-Abl tyrosine kinase. We have shown
previously that the negative growth regulator, CCN3, is down-regulated
as a result of Bcr-Abl kinase activity and that CCN3 has a reciprocal
relationship of expression with BCR-ABL (McCallum et al, Blood 2006;
108(5):1716–23). We now show that CCN3 confers growth regulation in
CML cells by causing growth inhibition and apoptosis.
To further investigate CCN3 mode of growth regulation, K562
CML cells were either transfected with CCN3 or treated with
recombinant CCN3 (rCCN3, Peprotech, UK). K562 cells were
transfected with CCN3 or empty vector (EV) using amaxa nucleo-
fector technology (Amaxa GmbH). Increased CCN3 expression
significantly reduced colony formation by 65.4%±18.8 when com-
pared to cells transfected with vector alone (p=0.027, n=3). Flow
cytometry identified an increased accumulation of cells within the
subG0 area as a consequence of CCN3 expression (Mean subG0 for
CCN3 21.8%±0.7 and EV 9.9%±4.6% respectively, p=0.027, n=3).
In addition, increased levels of CCN3 caused decreased phosphory-
lation of ERK2 and increased levels of cleaved caspase 3.
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(rCCN3) for 24 h and either plated in methyl cellulose culture or
analysed by flow cytometry and Western blotting. rCCN3 reduced the
colony formation capacity of K562 cells by 14%±2.8 in comparison to
untreated control (100%±2.3, p=0.015, n=3) and caused an increased
accumulation of cells within the subG0 area of cell cycle (Mean subG0
for rCCN3 treated cells 23.7%±6.4 and untreated control 9.3%±3.8, p=
0.014, n=3). rCCN3 treatment also resulted in decreased phosphoryla-
tion of ERK2 and an increase in levels of cleaved caspase 3.
To determine if primary human CML cells were responsive to
CCN3, CD34+ cells were extracted from CML peripheral blood patient
samples at diagnosis and treated with rCCN3 (range 1 nM to 10 pM) for
24 h prior to plating in methyl cellulose cultures. Primary CD34+ CML
cells treated with rCCN3 showed dose dependent inhibition of colony
formation (19.5%±4.0 (p=0.001), 17.8%±2.7(p=0.003) and 16.6%±4.6
(p=0.003) for 1 nM, 100 pM and 10 pM respectively, n=3).
CCN3 restores growth regulation in CML cells by inhibiting
cellular growth pathways and inducing apoptosis. Restoration of
CCN3 levels in CML cells may provide an additional therapeutic
strategy in the management of CML.
PROGNOSTIC ROLE OF CCN3 IN OSTESARCOMA
AND EWING’S SARCOMA
Katia Scotlandi, Piero Picci, Diana Zambelli and B. Perbal
Laboratory of Oncologic Research, Istitute Rizzoli, Bologna
Osteosarcoma and Ewing’s sarcoma, the two most common bone
tumors, still lack prognostic markers that could distinguish patients
before therapy and drive treatment choices. We assessed the
prognostic value of CCN1-3 genes, involved in fundamental biolog-
ical processes.=Expression of CCN1-3 was measured by either at gene
and protein level by microarray techniques or quantitative PCR and by
immunohistochemistry in 45 diagnosed localized tumors. Cancer
specific survival was estimated using the Kaplan-Meier method. In
addition we evalutated possible associations with osteoblastic differ-
entiation. While CCN3 is barely expressed in normal proliferating
osteoblasts and mesenchymal stem cells, its expression was generally
high in osteosarcoma and its level of expression did not correlate with
any specific osteoblastic differentiation genes. High expression of
CCN3 significantly correlated with worse prognosis in osteosarcoma.
This may be only partly explained by the association with the
expression of MRP1 and MRP4, two ABC transporters that also acted
as predictors of worse outcome in our study. In Ewing’s sarcoma we
confirmed the same type of association. High expression of CCN3
was associated with worse prognosis and higher metastatic risk.
Taking advantage of antibodies that recognize the different domains of
CCN we found that a high percentage of cases expressed a variant
type of CCN3 lacking the NH3 domain. Lack of this domain was also
associated with worse prognosis in patients treated with chemotherapy
and radiotherapy. Thus, we found that assessment for CCN3
expression levels at diagnosis may represent a useful molecular tool
to early identification of sarcoma patients with different prognosis.
CCN1/CYR61 ENHANCES THE METASTATIC POTENTIAL
OF HUMAN OSTEOSARCOMA CELL LINES
AND ACTIVATES THE AKT PATHWAY
Adam A. Sabile
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Osteosarcoma is the most frequent primary malignant bone tumor in
childhood with a high propensity for metastasis. Despite significantly
improved treatment strategies through the use of combined chemo-
therapy and surgery, patients with metastatic or recurrent disease
continue to have a poor prognosis.
Recently, CCN1/Cyr61 emerged as a multifunctional protein that
also stimulates angiogenesis and tumor growth. Aberrant expression
of CCN1/Cyr61 is associated with several patho-physiological
processes including tumorigenesis.
In this study, we demonstrated that CCN1/Cyr61 expression is
upregulated in highly metastatic human osteosarcoma cell lines, as
well as in primary tumor tissues of osteosarcoma patients. Moreover,
overexpression of CCN1/Cyr61 in osteosarcoma cell lines with low
metastatic potential enhanced their metastatic activity in-vitro.
In addition, we demonstrated that CCN1/Cyr61 activates AKT in a
specific manner and leads to the translocation of the cell cycle
inhibitor p21 from the nucleus to the cytosol. Thus, our data suggest a
role of CCN1/Cyr61 in the regulation of the metastatic process in
osteosarcoma which is likely mediated, at least in part, by the
stimulation of the AKT signaling and the cell cycle control.
CCN3 SUPPRESSES GROWTH AND INDUCES ACTIN
CYTOSKELETAL REORGANIZATION IN BREAST CANCER
CELLS
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Several lines of evidence, including a compilation from gene
expression analyses of cancer tumor arrays, demonstrate that the
expression of CCN3 is lower in higher-grade breast tumors.
Indeed, CCN3 has been shown to inhibit growth and proliferation
in many cell types, and its absence in high grade tumors is
therefore not surprising. Interestingly, recent data has also shown
that gap junction protein connexin43 (Cx43), whose expression is
similarly downregulated in aggressive breast tumors, upregulates
the expression of CCN3 in gliomas. We therefore investigate
whether 1) CCN3 negatively regulates growth in breast cancer
cells and 2) CCN3 as a possible downstream signaling mediator of
Cx43-dependent growth control. We performed gain/loss of
function studies in 2 breast cell lines—Hs578T cells that expressed
high levels of Cx43 and CCN3, and MDA-MB-231 cells with low
endogenous Cx43 and CCN3. Using standard growth proliferation
and migration assays, we determined that overexpression of CCN3
in MDA-MB-231 cells reduced growth but had little effect on
directed cell migration. Further analysis showed that CCN3
induced the formation of multiple actin-rich pseudopodia. Using
Cx43 shRNA to knock down Cx43 protein in Hs578T cells, we
observed a corresponding decrease in CCN3 expression, indicating
Cx43 is able to regulate CCN3 expression. On the other hand, a
reduction of CCN3 level by siRNA did not affect the expression
and coupling of Cx43, suggesting CCN3 is acting downstream of
Cx43. Cx43 are transmembrane proteins that can form channels to
allow the exchange of materials between cells, or interaction with
signaling molecules such as cell adhesion protein ZO-1 with its C-
terminal tail. To further delineate the relationship between Cx43
and CCN3, we used co-immunoprecipitation assays to confirm that
the C-terminal tail of Cx43 contains the CCN3-interacting sites. In
addition, we added fluorescent- labeled CCN3 protein to the
culture medium of Hs578T cells and observed the uptake and
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ing that secreted CCN3 can be internalized by breast cancer cells.
A small percentage of these vesicular CCN3 also appears to
associate with Cx43. Our results suggest Cx43 may modulate cell
growth by directly regulating the expression and localization of
CCN3.
CCN1: A NEW TARGET FOR CHEMOTHERAPEUTICAL
DRUGS IN BREAST CANCER TREATMENT
Ruth Lupu, Clara Diestre, Manjari Dimri and Ingrid Espinoza
Laboratory of Medicine and Pathology, Department of Experimental
Pathology, Cancer Center, Mayo Clinic, Rochester, Minnesota
The angiogenic factor CCN1, plays a key role in both the
maintenance and the enhancement of a malignant phenotype in
breast cancer. CCN1 is overexpressed in about 30% of triple
negative breast carcinomas, whereas that in normal breast tissues
are negligible. CCN1 expression is highly correlated with
advanced disease. Women with advanced breast cancer often
develop bone metastases with high CCN1 level expression.
Recently, we have demonstrated that CCN1 overexpression render
human breast cancer cells highly resistance to the microtubule-
interfering agent paclitaxel (Taxol), a drug of choice for the
treatment of metastatic breast cancer. Most of the patients with
breast cancer will develop bone metastases and they will receive
bisphosphonate treatment. Zoledronic acid, pharmaceutically
known as Zometa (ZOL), a third generation aminobisphosphonate,
inhibits bone resorption and might prevent development of new
osteolytic lesions induced by tumor metastases. Our data demon-
strate that CCN1 is a prime candidate to target for a large portion
of triple negative breast carcinomas. On the basis of this
consideration, since CCN1 gives a Taxol resistant phenotype and
ZOL has an effect on metastatic breast carcinomas, we tested the
effect of Taxol and ZOL in breast cancer cells overexpressing
CCN1 to determine whether the latter is a target for these drugs.
We have confirmed that expression of αvβ3, a CCN1 receptor, is
markedly up-regulated in breast cancer cells expressing CCN1. Our
most recent data demonstrate that functional blockade of αvβ3 with a
synthetic chemical peptidomimetic based upon the αvβ3 the RGD
(Arg-Gly-Asp) motif, is specifically cytotoxic towards CCN1-over-
expressing breast cancer cells. Pharmacological interference of the
CCN1/αvβ3 interaction restores Taxol efficacy. To verify that the
sole interaction between CCN1/αvβ3 integrin promotes chemo-
resistance, namely Taxane-resistance, we took advantage of a
CCN1 mutant with a point mutation at the position 125 of the
protein (D125A) and which lacks the ability to interact with αvβ3.
The studies showed that while CCN1 wild type induced Taxol
resistance of breast cancer cells, the CCN1 mutant resulted in cells
more sensitive to Taxol. Since CCN1 is a secreted protein, we can
envision that the identification of a CCN1/αvβ3 autocrine loop
suggests that targeting CCN1/αvβ3 may simultaneously prevent
breast cancer tumorigenesis, angiogenesis and chemoresistance. We
also establish that ZOL has a direct effect on CCN1 expression at
transcriptional and protein level in breast cancer cells. Remarkably,
ZOL inhibited branching and morphogenesis in 3D in Matrigel in
addition to anchorage independent growth of CCN1 overexpressing
cells. Collectively, these data demonstrate for first time a specific
effect of ZOL on a pro-angiogenic factor involved breast cancer
metastasis. Our data represents a new path for CCN1/αvβ3 targeted
therapy, and a novel molecular avenue in the management and of
metastatic breast cancer.
SUPPRESSION OF INVASIVE FRONT BY CCN5/WISP-2
IN BREAST CANCER IS MEDIATED THROUGH SILENCING
OF MICRO RNA-10B
Inamul Haque, Snigdha Banerjee, Gopal Dhar
and Sushanta K. Banerjee
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Metastatic cells are a subset of primary tumor cells that have acquired
the ability to complete a multi-step metastatic cascade, including
migration, dissemination, extravasation, and eventual proliferation at a
discontinuous secondary site. Understanding the molecular biology of
cancer metastasis may provide novel intervention strategies to control
metastatic lesions, and to improve the quality of life for the patients
with these advanced diseases. MicoRNAs are naturally occurring
single-stranded RNA molecules that post-transcriptionally regulate the
expression of target mRNA transcripts. Many of these target mRNA
transcripts are involved in cell proliferation, differentiation and
apoptosis, processes commonly altered during tumorigenesis. Recent
findings have shown that microRNA-10 b (miR-10 b) is highly
expressed in metastatic breast cancer cells and positively regulates cell
migration and invasion. Expression of miR-10 b is induced by Twist, a
transcription factor that binds to putative promoter of miR-10 b. Since
our recent studies proposed that CCN5 is a two-faced cancer gene and
may participate in preventing micro-invasion of breast cancer cells, we
hypothesized that CCN5 may regulate the invasive front through the
nullification of miR-10 b expression. We found that silencing of
CCN5 in ER-positive noninvasive breast tumor cell upregulates the
miR-10 b expression parallel with HIF-1a and Twist. Moreover, the
studies also showed that enhanced migration of CCN5 nullified MCF-
7 breast cancer cells can be repealed by anti-miR-10 b. Collectively,
these studies suggest that miR-10b is one of the key players in CCN5/
WISP-2-mediated regulation of micro-invasion. Furthermore, we
anticipate that the suppression of miR-10 b expression by CCN5
may be regulated by HIF-1a-Twist signaling pathway
IDENTIFICATION OF CCN PROTEINS AS SUBSTRATES
FOR KALLIKREIN-RELATED PEPTIDASES
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Human tissue kallikreins (KLKs or kallikrein-related peptidases) com-
prise a subgroup of 15 homologous secreted serine proteinases encoded
by a multigene family located on chromosome 19q13.4. KLKs are
expressed in a myriad of tissues and are associated with important
diseased states including cancer, inflammation and neurodegeneration. In
cancer, their expression is often correlated with patient prognosis. So far,
experimental evidence indicates that KLKs might promote or inhibit
cancer-cell growth, angiogenesis, invasion and metastasis through
degradation of growth-factor-binding proteins, activation of other
proteinases and proteinase-activated receptors, and cleavage of extracel-
lular-matrix components. Despite increasing interest in elucidating
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limited.Inthisstudy,weusedadegradomicapproachtoidentifypotential
substrates of this enzyme. MDA-MB-231 cells were treated either with
KLK12 or vehicle control in serum-free medium. After 30 min of
treatment, overlying media were collected and the protein content was
analyzed by mass spectrometry (OrbitTrap; Thermo Scientific). CCN1
was specifically identified in the medium of treated cells, suggesting that
KLK12mightcleaveandreleasethis proteinfromthecellsurface.Totest
this hypothesis, we investigated whether KLK12 digests CCN1 in vitro.
Recombinant CCN1 was treated with KLK12 for varying times and the
fragmentation products were analyzed by SDS-PAGE and mass
spectrometry (Maldi-TOF).Our results showed that KLK12 rapidly
cleaves CCN1 releasing two peptides fragments of 20.5 and 19.3 kDa.
Further in vitro studies revealed that all the members of the CCN family
can be digested by KLK12 with variable but comparable efficiency.
Then, we investigated whether CCN members could serve as substrates
for other KLKs (KLK1, 5, 6, 11, 13 and 14). We found that CCN1 and
CCN5 were more efficiently cleaved by KLK12 and KLK14. Experi-
ments are currently in progress to determine whether KLK-dependent
proteolysis of CCN proteins alters their functional properties.
THE CCN FAMILY MEMBER CCN6: INHIBITION OF CCN6
REGULATES E-CADHERIN EXPRESSION IN THE BREAST
EPITHELIUM THROUGH UP-REGULATION OF SNAIL
AND ZEB1
Wei Huang, Yanhong Zhang, Sooryanarayana Varambally,
Sofia D. Merajver and Celina G. Kleer
Department of Pathology and Comprehensive Cancer Center,
University of Michigan
Epithelial–mesenchymal transition (EMT) is an important process
during development by which epithelial cells acquire mesenchymal,
fibroblast-like properties and show reduced intercellular adhesion and
increased motility. E-cadherin has a central role of EMT, and its loss
in cancer is associated with de-differentiation, invasion, and metasta-
sis. CCN family members are secreted proteins implicated in
epithelial-stromal cross talks, important for development and cancer
progression. We previously reported that expression of CCN6 (or
WISP3, Wnt-induced secreted protein 3) was frequently down-
regulated in the highly aggressive inflammatory breast cancer and
that CCN6 has tumor suppressor functions in breast cancer.
The stable CCN6-dificient HME cell line was constructed using two
strategies: small interfering RNA-CCN6 in pSilencer2.1-U6 hygro and
short hairpin RNA in a lentiviral vector (pLKO.1). Cells were cultured
and observed for EMT-likes changes. CCN6 knockdown cells and
controls were subjected to Western blots for E-cadherin. Luciferase
assaystodetermine theeffect ofCCN6 inhibitionontheactivityoftheE-
cadherin promoter were performed. Protein and mRNA levels of the E-
cadherin transcriptional repressors Snail, Slug, Sip1 and Zeb1 was
investigatedbyWesternblotandreal-imeRT-PCR.CCN6-dificientHME
cells were treated with siRNA-Snail or siRNA-Zeb1.
CCN6 inhibition in HME cells caused EMT approximately 7 days
after stable transfection. This was accompanied by E-cadherin protein
and mRNA down-regulation, with decreased activity of the E-cadherin
promoter. By real-time RT-PCR, CCN6 inhibition led to an increase in
Zeb1 and Snail mRNAs, whereas there was no effect on the other E-
cadherin transcriptional repressors. Treatment of CCN6 knockdown
cells with either Snail or Zeb1 siRNAs rescued E-cadherin protein
expression.
Our results suggest an important role of CCN6 in regulating E-
cadherin expression through transcriptional mechanisms involving
Snail and Zeb1. We are now focused on the precise molecular
mechanism by which CCN6 regulates Snail and Zeb1 during EMT.
THE CCN1/α6β1 CONNECTION AND THE HORMONAL
RESPONSE IN BREAST CANCER
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CCN1 plays a key role in both the maintenance and the enhancement of
a malignant phenotype in breast cancer. The expression of CCN1 is
sufficient to promote the acquisition of estrogen-independent and
antiestrogens-resistant phenotype in breast cancer cells, apparently
through a αvβ3-integrin. However, α6β1-integrin is also associated
with invasive carcinoma, although its specific participation in the
hormonal response is unknown. Here, we investigated whether: 1)
Expression of a CCN1 mutant with substitutions in the α6β1-binding
domains (TM) impedes CCN1’s ability to induce an E2-independent
and/or the antiestrogens resistant phenotype, 2). CCN1 participates in
the regulation of Estrogen Receptor-transcriptional activity in MCF-7
cells and 3). CCN1 mutant impairs the ability of the cells to growth in
3D-Matrigel culture. MCF-7 cell lines stably expressing either the
CCN1-wild type (wt), CCN1-TM mutant or MCF-7/pBabe (empty
vector) were growth in E2 depleted conditions and subjected to
anchorage-independent growth assays in the presence of estrogen (E2
(10
−9 M) and antiestrogens [Tamoxifen (10
−7 M) and ICI 182,780
(10
−7 M)]. Our results show that CCN1-induced anchorage-independent
growth in the absence of E2 and in the presence of antiestrogens. In
contrast, MCF-7/TM mutation impaired this ability. These data suggest
that the CCN1-α6β1 interaction contributes to the CCN1-mediated
induction of E2 independent and antiestrogens resistant phenotype. To
determine whether CCN1/α6β1 interaction regulates the ER-transcrip-
tional activity, we used estrogen-response-element (ERE)-reporter
assays. E2-deprived cells were transfected with ERE-Luciferase. Then
cells were incubated with the treatments described previously and the
Luciferase activity was detected. Results showed that MCF-7/CCN1
cells exhibited a higher basal ERE-Luc activity and in response to E2
and antiestrogens than MCF-7 and MCF-7/TM cells. These data show
that blockage of the CCN1/α6β1 interaction abolishes the transcriptional
activation of ER, suggesting a genomic role for these proteins in MCF-7
cells. The 3D-matrigel culture showed that MCF-7/TM cells growth less
than MCF-7/CCN1 cells in the presence of E2 confirming the previous
results. Together these results support a possible nuclear role for CCN1
as a co-activator of ER, involved in the transcriptional activation of
proliferative and survival ERE-genes in breast cancer cells.
NOVEL TRANSCRIPTIONAL REGULATION OF CCN2/CTGF
BY NUCLEAR TRANSLOCATED MMP3
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118 Fifth international workshop on the CCN family of genesCCN2/CTGF, designated from Connective Tissue Growth Factor, is a
crucial regulator ofextra-cellular matrix (ECM), which promotes ECM
synthesis and stabilization.
As the family name clearly implies, matrix metalloproteases
(MMPs)are also localized to the ECM, where they function as
proteases, modulating cell signaling by cleaving proteins such as
matrix proteins, growth factors and growth factor receptors. We
previously reported that strong expression of CCN2/CTGF in
chondrocytic cells is through transcription enhancer dominant in
chondrocytes (TRENDIC).
In this workshop, we report that matrix metalloprotease-3 (MMP3)
is a novel TRENDIC-binding transcription factor for CCN2/CTGF
expression. First, MMP3 cDNA was cloned as a TRENDIC-binding
factor by southwestern screening. An interaction between MMP3 and
TRENDIC was confirmed by a gel shift assay and chromatin
immunoprecipitation. The CCN2/CTGF promoter was activated by
transfected MMP3, whereas a TRENDIC mutant of the promoter lost
the response. Also, the knock-down of MMP3 suppressed CCN2/
CTGF expression. By cytochemical and histochemical analyses,
MMP3 was detected in the nuclei of chondrocytic cells in culture
and also in the nuclei of normal and osteoarthritic chondrocytes in
vivo. The nuclear translocation of externally added recombinant
MMP3 was observed in 30 min after the addition, and six putative
nuclear localization signals in MMP3 were also found. Furthermore,
we determined that heterochromatin protein γ coordinately regulates
CCN2/CTGF by interacting with MMP3. These results indicated a
novel trans-activation mechanism of CCN2/CTGF by the nuclear
translocated MMP3 through binding with TRENDIC in chondrocytes.
Although MMPs historically had been recognized as a protease for
extra-cellular proteins, this study indicated that it is also a promoter of
ECM synthesis through CCN2/CTGF trans-activation. This novel
regulatory role of ECM may contribute to understanding the
mechanism of not only development of cartilage, but also pathogen-
esis of arthritis and fibrosis.
INTEGRIN-MEDIATED MATRIX SIGNALING IN CELL
DEATH AND SURVIVAL
Chih-Chiun Chen, Jennifer L. Young, Fan-E Mo, Viktor Todorović,
and Lester F. Lau*
Department of Biochemistry and Molecular Genetics, University of
Illinois at Chicago College of Medicine, 900 South Ashland Avenue,
Chicago, Illinois 60607
Regulated expression of the matricellular protein CCN1 (CYR61) is
essential for cardiovascular development, and is associated with
inflammation and tissue repair. During embryogenesis, CCN1 is
critical for the survival of arterial vascular cells and mesenchymal
cells of the cardiac cushion tissue, and Ccn1-null mice suffer aberrant
apoptosis in these cell types (Mo et al., Mol. Cell. Biol. 22: 8709–
8720; Circ. Res. 99: 961–969). CCN1 is an ECM-associated protein
that supports cell adhesion and spreading through interaction with
specific integrin receptors, and cell adhesion to CCN1 can promote
survival in specific cell types such as vascular endothelial cells.
However, in contrast to other matrix cell adhesive proteins, CCN1 can
also induce apoptosis in other cell types while supporting cell
adhesion and cell spreading (Todorović et al., J. Cell Biol. 171:
559–568). Thus, CCN1 can promote cell survival or cell death in a
cell type specific manner. Unexpectedly, CCN1 also acts as a powerful
regulator of the cytotoxicity of inflammatory cytokines such as tumor
necrosis factor a (TNFα)(Chen et al., EMBO J. 26:1257–1267). TNFα
regulates inflammation and immunity, but also induces cell death in a
context-dependent manner. Although TNFα is cytotoxic to certain
tumor cell lines, it triggers apoptosis in normal cells only when NFκB-
signaling or protein synthesis is blocked. We show that CCN1 can
unmask the cytotoxic potential of TNFα without perturbation of
NFκB-signaling or de novo protein synthesis, leading to rapid
apoptosis in the otherwise resistant primary human fibroblasts.
CCN1 acts through binding to integrins αvβ5, α6β1, and syndecan-
4, triggering the generation of reactive oxygen species (ROS) through
a Rac1-dependent mechanism via 5-lipoxygenase and the mitochon-
dria, leading to the biphasic activation of JNK necessary for apoptosis.
In contrast to ROS generation and apoptosis induced by TNFα in the
presence of cycloheximide, NADPH oxidase is not required for
apoptosis induced by CCN1/TNFα. Furthermore, mice with the
genomic Ccn1 locus replaced with an apoptosis-defective Ccn1 allele
are substantially resistant to TNFα-induced apoptosis in vivo. These
results indicate that CCN1 is a physiologic regulator of TNFα
cytotoxicity, providing the contextual cues from the extracellular
matrix for TNFα-mediated cell death.
INDUCTION OF CTGF BY TGF-Β1 IN OSTEOBLASTS:
INDEPENDENT EFFECTS OF SRC AND ERK ON SMAD
SIGNALING
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Connective tissue growth factor (CTGF/CCN2) is a cysteine rich,
extracellular matrix protein that acts as an anabolic growth factor to
regulate osteoblast differentiation and function. In osteoblasts, CTGF
is induced by transforming growth factor beta 1(TGF-β1) where it
acts as a downstream mediator of TGF-β1 induced matrix production.
The molecular mechanisms that control CTGF induction by TGF-β1
in osteoblasts are not understood. We have previously demonstrated
the requirement of Src, Erk and Smad signaling for CTGF induction
by TGF-β1 in osteoblasts. However, the potential interaction among
these signaling pathways in osteoblasts has not been examined. In this
study we demonstrate that TGF-β1 activates Src kinase in osteoblasts
(primary rat and rat osteosarcoma cell line) and that treatment with the
Src family kinase inhibitor, PP2, or two independent Src kinase
mutants (kinase-dead; kinase-dead and open) prevented Src activation
and CTGF induction by TGF-β1. The inhibition of Src kinase activity
prevented TGF-β1 induced Smad 2 & 3 activation and Smad nuclear
translocation in osteoblasts as determined by immunofluorescent and
Western blot analyses. In addition, inhibiting Src prevented Erk
activation. MAPKs such as Erk can modulate the Smad pathway
through directly mediating the phosphorylation of Smads or indirectly
through activation/ inactivation of required nuclear co-activators that
mediate Smad DNA binding. When we treated osteoblasts with the
Erk inhibitor, PD98059, it inhibited TGF-β1-induced CTGF promoter
activity and protein expression but had no effect on Smad activation or
Smad nuclear translocation. Using electro-mobility shift assays we
found that treatment with PD98059 impaired transcriptional complex
formation on the Smad binding element (SBE) of the CTGF promoter,
demonstrating that Erk activation was required for SBE transactiva-
tion. Taken together these data demonstrates that Src is an essential
upstream signaling partner of both Erk and Smads for TGF-β1
induction of CTGF in osteoblasts, and that Src and Erk have
independent effects on Smad signaling required for the formation of
a transcriptionally active complex that regulates CTGF promoter
activity and expression. Future studies will focus on examining
Fifth international workshop on the CCN family of genes 119whether these interactions are unique to osteoblasts compared to other
non-osteoblast cells or lines. Evaluation of the precise regulation of
CTGF expression in osteoblasts is important to more fully understand
its effects on osteoblast differentiation and function.
CROSS-TALK BETWEEN CTGF AND TGF-Β1
IN MESENCHYMAL STEM CELL CONDENSATION
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Condensation or the aggregation of mesenchymal stem cells (MSCs)
precedes chondrocyte differentiation and is required for cartilage
formation. CTGF is a matricellular protein that has been found to be
expressed during MSC condensation in vivo. It has been reported that
CTGF has the ability to bind TGF-β1 and modulate its effects. Using
C3H10T1/2 MSCs as a model for mesenchymal condensation, we
have shown previously that TGF-β1 induces MSC condensation and
this induction is mediated by CTGF. In this study, we were interested
in examining whether CTGF treatment or overexpression can mediate
MSC condensation in the absence or presence of TGF-β1. C3H10T1/
2 MSCs were either treated with rCTGF or infected with adenovirus
over-expressing CTGF tagged with GFP. Primary limb bud MSCs
treated with rCTGF did not condense. C3H10T1/2 MSCs infected
with adenovirus expressing only CTGF demonstrated a 6-7 fold
increase in CTGF expression when compared to GFP infected, control
cells. Similar to the primary limb experiment, C3H10T1/2 cells
infected with CTGF adenovirus did not condense. Surprisingly, TGF-
β1 induced MSC condensation was inhibited in cells overexpressing
CTGF. These results suggest that sustained overexpression of CTGF is
not sufficient to induce mesenchymal cell condensation and has an
inhibitory effect on TGF-β1-induced MSC condensation. We next
examined the effect of CTGF overexpression on MSC adhesion and
spreading associated with vinculin localization at focal adhesions and
actin cytoskeletal reorganization. Cells overexpressing CTGF spread
more robustly with increased vinculin at sites of focal adhesions
associated with the formation of lamelopodia when compared to cells
infected with GFP virus alone. We next examined the signaling
pathways associated with MAP kinase family and Smads to evaluate
differences between TGF-β1-induced MSC condensation and the
inhibitory effect of CTGF overexpression on MSC condensation
induced by TGF-β1. Cells infected with GFP (control) and CTGF
viruses, were treated with TGF-β1 at different time points and
examined for the activation of MAP kinases and Smads. Phosphor-
ylated P38, Jnk and Erk were increased in the GFP-infected and
CTGF-infected MSCs treated with TGF-β1, suggesting that the MAP
kinase family members are not responsible for the inhibitory effect of
CTGF over-expression on TGF-β1-induced MSCs condensation.
Activation of Smad signaling in CTGF-infected cells treated with
TGF-β1 compared to GFP-infected cells treated with TGF-β1,
showed a maximum Smad2/3 activation at early time points in cells
overexpressing CTGF, compared to GFP-infected cells, suggesting
that the Smads signaling pathways might be responsible for the
inhibitory effect of CTGF-overexpression on MSCs condensation
induced by TGF-β1. Collectively, these data suggest that CTGF by
itself does not induce MSCs condensation and that CTGF over-
expression inhibits TGF-β1-induced MSCs condensation, at least in
part, via changes in Smad activation. Work is underway to examine
the role of CTGF ablation during mesenchymal condensation in
vivo and determine whether CTGF is sufficient to induce MSCs
condensation.
TGF-b RECEPTOR I KINASE ACTIVITY IS REQUIRED
FOR CTGF/CCN-2 EXPRESSION INDUCED BY TGF-b
AND LPA
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Connective tissue growth factor (CTGF/CCN-2) is the main growth
factor that induces fibrosis. CTGF is increased in fibrotic diseases
such as cardiac remodeling, renal disorders and muscular dystrophies
such as Duchenne. In these diseases and other fibrotic disorders,
several extracellular signals have been proposed to regulate the levels
of CTGF, and induce the beginning and progression of fibrosis, such
as transforming growth factor beta (TGF-b) and lysophosphatidic acid
(LPA). In myoblasts we have demonstrated that the expression of
CTGF is induced by TGF-b and LPA.
In this study, the regulation of CTGF expression by TGF-b and
LPA in skeletal muscle cells was evaluated. TGF-b and LPA increased
CTGF expression determined by Northern blot and a specific plasmid
reporter for CTGF transcriptional activity containing 5,1 Kb sequence
of mouse CTGF promoter. When TGF-b and LPA were added
together, CTGF expression augmented in an additive fashion.
Interestingly, cells incubated with a specific inhibitor of TGF-b
receptor I kinase activity (SB 431542), showed that CTGF expression
induced by TGF-b and/or LPA was abrogated. Transfection experi-
ments using plasmids of a dominant negative form of TGF-b receptor
II or Smad-7 (both inhibitors of TGF-b signaling pathway) with a
plasmid reporter for CTGF transcriptional activity showed that TGF-b
pathway was required for CTGF expression induced by LPA and
TGF-b. These results suggest a possible crosstalk between TGF-b and
LPA-dependent pathway signaling related to CTGF expression.
Interestingly, LPA was not able to activate TGF-b pathway signaling
by itself evaluated by Smad-2 phosphorylation and Smad-4 nuclear
translocation.
This study suggest that TGF-b receptor I kinase activity and Smad
dependent pathway are required for CTGF expression induced by
TGF-b and particularly by LPA.
Supported by FONDAP, MIFAB, CARE, MDA 89419
NUCLEAR LOCALIZATION OF CCN5, A CLASSIC
MATRICELLULAR PROTEIN
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Hyperproliferation of vascular smooth muscle cells is the hallmark of
restenosis following vascular surgery. CCN5, a growth arrest specific
protein in smooth muscle cells, dose-dependently inhibits vascular smooth
muscle cell proliferation and migration in vitro. In the mouse carotid
ligation model for vascular injury, CCN5 is lost during the proliferative
stages of the response-to-injury process, and returns once the smooth
muscle cells stop proliferating and the lesion is mature. Importantly,
restoring CCN5 to the carotid artery following the injury process
almost completely suppresses smooth muscle cell proliferation and
restenosis. Furthermore, CCN5 inhibits proliferation of other smooth
muscle cells, including uterine and airway. CCN5, like the other CCN
family proteins, was originally discovered as a matricellular protein, a
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immunohistochemical and immunofluorescence data in vascular,
uterine, and airway smooth muscle cells suggests that CCN5 is also
a nuclear protein. Confocal microscopy analysis revealed that CCN5
has a punctate nuclear matrix localization pattern, with complete
nucleolar exclusion, in addition to its classical matricellular localization.
Therefore, we carried out cell fractionation studies to analyze the
subcellular localization of CCN5. Subcellular fractions were separated
and analyzed by Western blot analysis with a CCN5 specific antibody.
We obtained fractions from two different cell populations: exponentially
growing and growth arrested cells. Protein analysis indicates that
distinct CCN5 variants are present in both quiescent and exponentially
growing cells. However, there are significant differences in which
variants are expressed based on subcellular fraction and growth state.
Future work aims to characterize the biochemical and functional
properties of both nuclear and non-nuclear variants present in smooth
muscle cells in different growth states.
EARLY EMBRYONIC EXPRESSION OF CCN5 IN MOUSE
EMBRYOS
Ronald B. Myers, Kibibi Rwayitare, Janis Lem, John J. Castellot Jr.
Department of Anatomy and Cell Biology
Tufts University School of Medicine, Boston MA, USA
To date, CCN5 distribution in early developing rodents has not been
mapped comprehensively. CCN5 strongly inhibits adult smooth muscle
cell proliferation and motility. Its anti-proliferative action predicts that
CCN5 would not be present in developing tissues until the proliferation
phase of tissue morphogenesis is complete. However, estrogen induces
CCN5 expression in epithelial and smooth muscle cells, suggesting that
CCN5 might be widely expressed in embryonic tissues exposed to high
levels of estrogen. E9.5–E16.5 dpc murine embryos have already been
analyzed by immunohistochemistry. CCN5 was detected in nearly all
developing tissues at age E9.5, and gradually developed a more tissue-
specific expression pattern as age progressed. The widespread expression
pattern of CCN5 in most embryonic tissues suggests a diverse range of
functions for CCN5. The importance of CCN5 in early embryonic
expression became evident while we were attempting to produce CCN5
overexpressing mice. Our CCN5 construct has been injected several times
in order to produce transgenic mice, however litters have not yielded any
founder mice, and have been small in size, suggesting a possible
embryonic lethality. Current immunohistochemistry studies are focused
on CCN5 expression from the fertilized ovum stage until E8.5. These
studies have already shown widespread expression of CCN5 as early as
E4.5 and all the way up to E8.5. Different IHC techniques are required for
embryos younger than E4.5, but these studies are underway. Preliminary
Data shows that CCN5 is present in single cell embryos. This data will be
not only be important for understanding the function of CCN5, but also
critical in the production of our CCN5 overexpressing mouse.
A THREE DIMENSIONAL CELL CULTURE MODEL
TO STUDY THE FUNCTION OF CCN6 IN BREAST
TUMORIGENESIS
Anupama Pal and Celina G. Kleer
Department of Pathology and Comprehensive Cancer Center, Univer-
sity of Michigan
We have identified a role for CCN6 in breast tumorigenesis and in the
regulation of epithelial cell differentiation. We hypothesize that CCN6
mediates epithelial-stromal cross-talk during breast cancer development,
and that inhibition of CCN6 in the mammary epithelium may result in
morphologic and functional changes toward and invasive phenotype. To
test this hypothesis it is necessary to closely recapitulate the
microenvironment that the cells encounter in vivo. Thus, we set out to
develop three dimensional cell cultures with epithelial and stromal
components. The stable CCN6-dificient HME cell line was constructed
using short hairpin RNA in a lentiviral vector (pLKO.1). shRNA
and control cells were cultured in matrigel over a 20 day period and
analyzed for their ability to form acini with central lumens. Invasive and
metastatic breast cancer cells SUM149 and MDA-MB-231 cells were
also cultured under these conditions, and served as controls. Immuno-
fluorescence was performed to detect CCN6, and proteins involved in
differentiation including cytokeratins, the myoepithelial cell marker p63,
and integrins. We successfully developed 3-dimensional cell cultures of
HME shRNA CCN6 and controls, as well as cultures of SUM149 and
MDA-MB-231 breast cancer cells. The HME cells transfected with the
empty vector control formed well-organized acini with central lumens.
We observed that CCN6 inhibition caused a striking morphological
change. HME shRNA CCN6 cells did not form acini, but elongated
tubular structures with extensive branching and connections, which
recapitulated the growth of cancerous cells. These cells also had
abnormal localization of integrin staining as well loss of expression of
epithelial cell markers. Our results show that three dimensional cultures
more closely recapitulates the in vivo setting and allow detailed study of
CCN6 function. Given the phenotype that we found, we are exploring
the effect of CCN6 on the expression of proteins needed for invasion
and degradation of the extracellular medium including matrix metal-
loproteinases, which will provide insights into CCN6 function in the
breast.
INVOLVEMENT OF CYR61 IN GROWTH, MIGRATION,
AND METASTASIS OF PROSTATE CANCER CELLS
Zhi-Jian Sun, Yan Wang, Zhen Cai, Ping-Ping Chen, Xiang-Jun Tong
and Dong Xie
Laboratory of Molecular Oncology, Institute for Nutritional Sciences,
Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences, Shanghai 200031, China
Cyr61 has been reported to participate in the development and
progression of various cancers, however, its role in prostate caner still
remains poorly understood. In the present work, we explored the
function of Cyr61 in a series of malignant prostate cancer cell lines,
including LnCap, Du145 and PC3. MTT and crystal violet assays
demonstrated that Cyr61 was essential to the proliferation of prostate
cancer cells. Soft agar assay and xenograft analysis showed that
downregulation of Cyr61 suppressed the tumorigenicity of Du145
cells both in vitro and in vivo. Either silencing the cellular Cyr61 by
RNAi or neutralizing the endogenous Cyr61 by antibody inhibited the
migration of Du145 cells. In contrast, purified protein of Cyr61
promoted the migration of LnCap cells in a does depended manner.
These results suggested that Cyr61 was involved in the migration of
prostate cancer cells. We also observed the accumulation of mature
focal adhesion complexes associated with the impaired migration via
Cyr61 downregulation. And further studies showed that Cyr61
regulated the level of activated Rac1 as well as its downstream
targets, including phosphorylated JNK, E-Cadherin and p27kip1,
which are key molecules involved in cell growth, migration and
invasion (Bremnes et al., 2002; Ziober et al., 2001). The in vivo
mouse tail vein injection experiment revealed that Cyr61 affected the
metastatic capacity of Du145 cells, suggesting that Cyr61 was
required for prostate tumor metastasis. Altogether, our results
demonstrated that Cyr61 played an important role in the tumorigenic-
ity and metastasis of prostate cancer cells, which will benefit the
development of therapeutic strategy for prostate cancers.
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OF INITIATION AND PROGRESSION OF DIABETIC
NEPHROPATHY
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Thirty to 40% of diabetic patients will develop diabetic nephropathy,
whereas the rest will remain free of this complication for decades.
Hypertension and hyperglycemia are established casual factors driving
progression once started. However, the initial determinants and the
exact pathways remain a mystery. While this is not considered to be an
“inflammatory disease” per se, current evidence points to elements of
an autoimmune response with possible persistent low levels of
inflammation as an initiating factor and a driver of fibrotic
progression. We explored cytokines as early factors that may predict
those patients destined for diabetic nephropathy, thus allowing an
earlier and more focused treatment. CCN2 mRNA is greatly
upregulated early in experimental diabetes and is excreted in urine
as early as 2 weeks after the onset of hyperglycemia. Another
cytokine, macrophage chemoattractant protein-1 (MCP-1 or CCL-2) is
often upregulated at sites of inflammation, and is a possible player in
diabetic nephropathy. We studied patients assigned to groups, 1)
diabetic (D), but without albuminuria (no signs of clinical nephrop-
athy), 2) diabetic with microalbuminuria (DM) (early clinical
nephropathy), or 3) diabetic with proteinuria (DP) (advanced
nephropathy). Patients were studied over 6 years and were classified
as demonstrating progression to renal impairment if serum creatinine
rose at least twice, or they became dialysis dependent. Urinary CCL-2/
creatinine ratios were significantly higher in patients with DP (3.3-fold
higher than D, and 2.1-fold higher than DM patients, p<0.01). In
contrast, urinary CCN2/creatinine ratios were greatly elevated in both
DM and DP patients (125–and 74-fold higher than D patients
respectively, p<0.01 and p<0.05 respectively). Urinary CCL-2 levels,
but not CCN2, were also 4-fold higher in patients with diabetic
retinopathy as compared to those without retinopathy (p<0.0005).
Urinary CCL-2, but not CCN2, correlated with the rate of deteriora-
tion of estimated glomerular filtration rate (eGFR), p<0.0005). In
contrast, urinary CCN2, but not CCL-2, correlated with progression of
microalbuminuria (, p<0.05) and the baseline eGFR (. p<0.05). The
occurrence of increased urinary CCN2 associated with early disease
and CCL-2 with later disease, appears in contrast with the more
general paradigm of inflammation followed by fibrosis. It also
suggests both that a combination of such new markers may be useful
in accessing the risk of progression, and that these cytokines may be
important in the initiation and progression of the disease.
This study was supported by project grant from Hammersmith
Hospital Special Trustee, the American Diabetes Association (BLR)
and the Juvenile Diabetes Association (BLR).
CCN3/NOV IS RECRUITED, TRAFFICKED AND MODIFIED
DURING ALL-TRANS RETINOIC ACID INDUCED
NEURONAL DIFFERENTIATION ON A 3D MATRIX:
ANALYSIS USING DOMAIN SPECIFIC ANTIBODIES
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CCN3/NOV is a secretable, matrix associated protein that has previously
been demonstrated to be expressed in different areas of the early
developing brain of rats and has been postulated to play a role in the
establishment and maintenance of specific brain functions. We developed
an in-vitro CNS like neuronal differentiation model using the NT2/D1
teratocarcinoma cell line grown on a 3D matrix to assay the role of CCN3
during neuronaldifferentiation.
The differentiation of neurons was accomplished by treating NT2/
D1 with all-trans retinoic acid (ATRA) over 15 days on an Ultraweb
matrix that has been shown to simulate 3D in-vivo matrix morphol-
ogy. Neuronal maturation was stimulated by cell cycle inhibitors
cytosine arabinoside, uridine and 5-fluoro-2'-deoxyuridine for an
additional 5 days. CCN3 expression was assessed at 5 day intervals
by western blot and immunocytochemistry using domain specific
CCN3 antibodies (NH2-NH5) Following ATRA induced differentia-
tion, detection of full-length 46 KDa CCN3 decreased with the NH2
antibody and dramatically increased with NH4. Detection of the
truncated 32 KDa CCN3 form by the NH3 and NH4 antibodies was
also dramatically increased. While there was little change detected in
the 46 KDa CCN3 using the original K19M antibody, a larger 48 KDa
band, suggesting post translational modification, was detected follow-
ing the appearance of mature looking neurons. Secretion of the
46 KDa form of CCN3 into the medium was detected starting from
day 10 coincident with increased neurofilament expression. Immuno-
cytochemistry showed an increase in cytoplasmic expression and also
nuclear localization of CCN3 in neurites with K19M, NH3, NH4 and
NH5. K19M, NH4 and NH5 antibodies were also able to localize
CCN3 in neuronal processes.
We conclude that CCN3 likely plays a key role during ATRA
induced neuronal differentiation, as seen by its increased nuclear
trafficking and expression. Increased secretion by maturing neurons
suggests that CCN3 could have an extracellular role during neuronal
differentiation. Differential detection of CCN3 by antibodies directed
against the different domains of CCN3 suggests possible functional
relevant conformational changes and protein interactions during
neuronal differentiation and maturation.
PROGRAM
Saturday October 18, 2008
20:00
Herman Yeger
Welcome
Bernard Perbal
Opening Remarks
20:30
Peter Butler, Bernard Perbal
Springer Award Presentation
21:00
Paul Bornstein
Plenary Lecture
Matricellular proteins regulate cell function: studies of thrombospondins
1 and 2
Sunday October 19, 2008
Session I: CCN Structure/Function; Expression (I)
Chairs: Gary Fisher; Masaharu Takigawa
122 Fifth international workshop on the CCN family of genes8:30–8:55
Ravi Acharya
The CCN family of proteins: structure-function relationships
8:55–9:20
Satoshi Kubota
Nucleophosmin/b23: a multifunctional regulator that determines the
fate of CCN2 mRNA
9:20–9:45
Toshihiro Ohgawara
Regulation of chondrocytic phenotype by microRNA 18a: involve-
ment of CCN2/CTGF as a major target gene
9:45–10:10
Claudio Cabello-Verrugio
CTGF/CCN2 expression induced by TGF-b is modulated through a
mechanism dependent of decorin and LRP-1
10:10–10:35
Chundo Oh
identification of sox9 binding site in ccn2 (CTGF) gene by use of
CHip on CHIP analysis
Session II: CCN Structure/Function; Expression (II)
Chairs: John Castellot; Enrique Brandan
11:00–11:25
Brahim Chaqour
Mechanical regulation of the Cyr61/CCN1 gene Requires the
combined activity of the myocardin-related transcription factor
(MRTF) -A and P300/CBP in smooth muscle cells
11:25–11:50
Douglas Hamilton
Periostin is Expressed in Human Skin and is Regulated by Mechanical
Strain
11:50–12:15
Lan Wei
Functional and biochemical assessment of CCN5 targeted to the
nucleus
12:15–12:40
Hirokazu Okada
Poly(ADP-ribose) polymerase-1 (parp-1) and parp-1 binding element
(pbe) enhance murine ccn2 gene transcription in proximal tubular
epithelial cells (ptec)
Session III: Osteogenesis and Chondrogenesis (I)
Chairs: David Brigstock; Robert Lafyatis
14:15–14:40
Masaharu Takigawa
Roles of CCN2 in skeletal growth and regeneration–requirement for
both endochondral and intramembranous bone formation-
14:40–15:05
Fayez Safadi
Skeletal phenotype in transgenic mice over-expressing CTGF in cells
of the osteoblast lineage
15:05–15:30
Faith Hall-Glenn
CCN1 and CCN2 are essential for chondrogenesis
15:30–15:55
Ken-ichi Katsube
CCN3 and NOTCH/BMP signals
15:55–16:20
Andrew Leask
FAK/SRC suppresses early chondrogenesis: central role of CCN2
Session IV: Osteogenesis and Chondrogenesis (II)
Chairs: Havard Attramadal; Ben Alman
16:40–17:05
Mark Erwin
CTGF/CCN-2 is produced by non-chondrodystrophic canine inter-
vertebral disc-derived notochordal cells and upregulate nucleus
pulposus aggrecan gene expression
17:05–17:30
Karen Lyons
CCN2 is required for vascular remodeling in vivo
17:30–17:55
Mukesh Jain
KLF15 regulates the cardiac response to stress
17:55–18:20
Ursula Kees
The role of CTGF in paediatric acute lymphoblastic leukaemia
Monday October 20, 2008
Session V: Pathobiology (I)
Chairs: Ken-Ichy Katsube; Satoshi Kubota
8:30–8:55
Laure Rittié
Expression of CCN proteins in normal human skin in vivo and after
wound healing
8:55–9:20
Andrew Leask
Connective tissue growth factor promoter activity in normal and
wounded skin
9:20–9:45
Taihao Quan
Ultraviolet irradiation induces CYR61/CCN1, a novel mediator of
collagen homeostasis, via activation of transcription factor AP-1 in
human skin dermal fibroblasts
9:45–10:10
Kirsten Bielefeld
The interaction of β-catenin with extra-cellular matrix components in
dermal fibroblasts during wound healing
10:10–10:35
George Yang
The role of the matricellular protein del1 in bone fracture healing
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Chairs: Lester Lau; Margarete Goppelt-Struebe
11:00–11:25
Mary Lou Cutler
Connective tissue growth factor (CTGF/CCN2) as a regulator of β1
integrin-mediated cell adhesion and survival during lactogenic
differentiation of mouse mammary epithelial cells
11:25–11:50
M. Shakil Ahmed
CCN2/CTGF–cardioprotective factor in myocardial ischemia/reperfu-
sion injury and heart failure
11:50–12:15
Stephen Twigg
High glucose and free fatty acid adverse effects on cardiac myocytes
are mediated by ccn2/connective tissue growth factor (CTGF)
through TrkA
12:15–12:40
Roel Goldschmeding
Balancing CCN-2 (CTGF) and BMP(s) in complications of diabetes
mellitus
Session VII: Fibrosis (I)
Chairs: Brahim Chaqour; Bruce Riser
14:10–14:35
Takako Hattori
CCN2/CTGF is transactivated through its enhancer element by Sox9
in fibroblasts: possible roles in fibrosis
14:35–15:00
Joshua Russo
In vivo effects of CCN5 overexpression in fibroids
15:00–15:25
Shiwen Xu
Microvascular pericytes express CCN2 in tissue fibrosis
15:25–15:50
Alpdogan Kantarci
Epithelial and connective tissue cell CTGF/CCN2 expression in gingival
fibrosis: role of epithelial-mesenchymal transition
Session VIII: Fibrosis (II)
Chairs: Karen Lyons; Andrew Leask]
16:20–16:45
Enrique Brandan
Fibrosis in duchenne muscular dystrophy; role of CCN2 and its
potential inhibition by decorin
16:45–17:10
Philip Trackman
Tissue-specific regulation of CCN2/CTGF in gingival fibroblasts and
its relationship to gingival fibrosis
17:10–17:35
Bruce Riser
CCN3 (Nov) is a negative regulator of CCN2 (CTGF) and a novel
endogenous inhibitor of fibrosis in experimental nephropathy
17:35–18:00
David R Brigstock
Targeted CCN2 gene therapy in experimental liver fibrosis
18:00–18:25
Margarete Goppelt-Struebe
Cell type-specific regulation of connective tissue growth factor by
hypoxia
Tuesday October 21, 2008
Educational Session: From Matricellular to Extracellular
Chairs: Paul Bornstein, David Brigstock, Margarete Goppelt-
Struebe, Lester Lau, Karen Lyons, Andrew Leask, Bernard
Perbal, Masaharu Takigawa
9:00–9:35
Aleksander Hinek
Elastin receptor subunits facilitate elastic fiber assembly and modulate
cell proliferation
9:35–10:10
William G. Cole
Abnormal extracellular matrices in rare and common disorders
10:40–11:15
Ren-Ke Li,
Cell transplantation and gene therapy preserves matrix homeostasis: a
novel paracrine mechanism
11:15–11:50
Katharine Sodek,
MT1-MMP and contractility mediate invasive behavior by ovarian
cancer cells
Round Table Discussion: 11:50–12:10
Session IX: Pathobiology (III)
Chairs: Celina Kleer; Ruth Lupu
13:45–14:10
Viviana Vallacchi
CCN3 promotes melanoma progression by regulating integrin expres-
sion, adhesion and chemoresistance
14:10–14:35
Lynn McCallum
CCN3 restores growth regulation in Chronic Myeloid Leukaemia
14:35–15:00
Katia Scotlandi
Prognostic role of CCN3 in ostesarcoma and Ewing’s sarcoma
15:00–15:25
Adam A. Sabile
CCN1/cyr61 enhances the metastatic potential of human osteosar-
coma cell lines and activates the AKT pathway
Session X: Pathobiology (IV)
Chairs: Philip Trackman
124 Fifth international workshop on the CCN family of genes16:00–16:25
Wun-Chey Sin
CCN3 suppresses growth and induces actin cytoskeletal reorganiza-
tion in breast cancer cells
16:25–16:50
Ruth Lupu
CCN1: A new target for chemotherapeutical drugs in breast cancer
treatment
16:50–17:15
Sushanta Banerjee
Suppression of invasive front by CCN5/wisp-2 in breast cancer is
mediated through silencing of microRNA-10b
17:15–17:40
Yves Courty
Identification of CCN proteins as substrates for kallikrein-related
peptidases
Wednesday October 22, 2008
Springer Scholarships
Chairs: Stephen Twigg; Sandra Irvine
8:30–8:55
Wei Huang
The CCN family member CCN6: Inhibition of CCN6 regulates E-
cadherin expression in the breast epithelium through up-regulation of
Snail and Zeb1
8:55–9:20
Ingrid Espinoza
The CCN1/α6β1 connection and the hormonal response in breast cancer
9:20–9:45
Takanori Eguchi
Novel transcriptional regulation of CCN2/CTGF by nuclear trans-
located MMP3
CCN in Cell Death and Survival
9:50–10:15
Lester Lau
Integrin-mediated matrix signaling in cell death and survival
10:15–11:15
Concluding remarks and presentation of the next meeting
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